earliest
known
rout
vaccin
respiratori
intranas
insuffl
powder
scab
materi
contain
variola
viru
smallpox
patient
reportedli
practic
china
earli
centuri
ad
see
chapter
cutan
rout
variol
involv
break
skin
sharp
instrument
use
india
perhap
earli
china
document
centuri
variol
supplant
safer
cutan
applic
materi
cowpox
lesion
method
vaccin
known
centuri
first
publish
edward
jenner
experi
hypoderm
inject
introduct
needl
syring
ns
centuri
pravaz
rynd
wood
began
new
era
medicin
pasteur
use
pravaz
syring
inocul
sheep
fame
control
challeng
experi
demonstr
protect
anthrax
honor
dr
jenner
broaden
predecessor
termvaccinationto
mean
administr
immun
agent
variou
diseas
smallpox
accept
germ
theori
result
steril
medic
equip
earli
centuri
mass
product
needl
glass
later
plastic
syring
mid
centuri
hypoderm
inject
becam
norm
conveni
accur
certain
administr
vaccin
mani
drug
regrett
asept
practic
ignor
mani
develop
countri
nonmedicalintravenousdrug
user
everywher
lead
widespread
iatrogen
selfinflict
diseas
transmiss
era
decri
inject
centuri
drawback
ns
includ
needlestick
injuri
health
care
worker
needlephobia
discomfort
patient
face
increasingli
crowd
immun
schedul
cost
complex
safe
dispos
sharp
medic
wast
stream
earli
centuri
new
target
diseas
control
erad
expans
philanthrop
effort
make
expens
new
vaccin
afford
world
children
promis
result
novel
techniqu
stimul
research
vaccin
deliveri
avoid
ns
may
dosag
spare
prepared
effort
threaten
pandem
bioterror
also
rekindl
past
interest
novel
needlefre
method
mass
vaccin
campaign
exist
potenti
altern
convent
intramuscular
im
subcutan
sc
vaccin
ns
well
oral
ingest
classifi
three
major
categori
cutan
vaccin
jet
inject
respiratori
vaccin
cutan
rout
may
subdivid
classic
intraderm
id
via
convent
needl
passiv
diffus
without
chemic
enhanc
adjuv
disrupt
penetr
stratum
corneum
mechan
contact
heat
electr
light
jet
inject
involv
pressur
liquid
highveloc
stream
reach
target
im
sc
id
tissu
respiratori
vaccin
deliv
airborn
particl
via
nose
mouth
deposit
onto
mucos
surfac
upper
lower
airway
mention
skin
one
first
tissu
variola
smallpox
viru
later
crossprotect
cowpox
viru
introduc
prevent
smallpox
rout
remain
standard
smallpox
vaccin
contain
vaccinia
viru
see
chapter
well
administ
bacil
bcg
prevent
tuberculosi
see
chapter
cutan
rout
demonstr
hypothet
advantag
deliveri
method
describ
review
other
reduc
dosag
variou
vaccin
skin
compar
full
dosag
muscl
fat
shown
tissu
dosagespar
abil
use
vaccin
scarc
unafford
full
dosag
skin
also
least
invas
rout
thu
theori
cutan
deliveri
new
antigen
less
like
result
unanticip
seriou
advers
reactionsfor
exampl
intussuscept
first
american
oral
rotaviru
vaccin
bell
paralysi
seventh
cranial
nerv
first
european
intranas
influenza
vaccin
occasion
abscess
nerv
injuri
needl
inject
muscl
fat
cours
bcg
smallpox
vaccin
deliv
skin
alway
benign
rare
may
result
uncontrol
replic
spread
live
antigen
caus
seriou
complic
particularli
immunocompromis
patient
nevertheless
skin
reaction
gener
easier
detect
earli
access
palli
activ
therapeut
antiinflammatori
agent
reaction
deeper
tissu
final
success
deliveri
antigen
cutan
vaccin
rel
sure
although
certain
gold
standard
needl
inject
needl
lack
cooper
infant
children
overcom
firm
restraint
contrast
oral
dose
spit
vomit
intranas
dose
sneez
block
mucoid
purul
rhiniti
pulmonari
deliveri
method
requir
patientiniti
inhal
see
figur
may
take
second
minut
administ
mask
prong
see
figur
b
e
f
drawback
may
rais
doubt
success
deliveri
antigen
unstandard
inconsist
nomenclatur
describ
vaccin
target
skin
found
literatur
eg
cutan
dermal
epicutan
epiderm
intracutan
intraderm
intraepiderm
intraepitheli
patch
percutan
skin
topic
transcutan
transderm
often
prefix
latin
intra
per
tran
greek
epi
origin
pair
heterolingu
root
term
skin
etymolog
derma
g
cuti
l
recent
coinag
result
commerci
intent
claim
trade
name
among
synonymi
chapter
cutan
vaccin
prefer
term
encompass
method
deliveri
antigen
anywher
onto
skin
classic
intraderm
inject
intraderm
id
gener
reserv
type
cutan
vaccin
bolu
liquid
deposit
dermi
rais
visibl
bleb
tradit
mantoux
inject
discuss
outermost
section
skin
epidermi
stratifi
squamou
epithelium
usual
mm
thick
mm
palm
sole
figur
stratum
malpighii
layer
compris
primari
compon
epidermi
divid
grow
keratinocyt
serv
structur
functionlimit
passag
water
moleculesand
immunolog
role
keratinocyt
germin
basement
membran
demarc
boundari
epidermi
deeper
dermi
cell
grow
flatten
matur
senesc
increasingli
superfici
strata
reach
surfac
slough
main
product
cell
keratinohyalin
dens
lipid
help
form
waterproof
barrier
later
edg
adjac
keratinocyt
tightli
link
desmosom
maintain
strength
epidermi
also
contribut
resist
passag
foreign
matter
molecul
topmost
horni
layer
epidermi
stratum
corneum
compris
stagger
cours
dead
keratinocytesalso
known
corneocytesin
lipid
bilay
matrix
stack
cell
thick
princip
obstacl
introduct
vaccin
antigen
cutan
vaccin
epidermi
basement
membran
lie
dermi
mm
thick
fibroblast
fine
collagen
elast
fiber
skin
organel
includ
small
blood
vessel
lymphat
vessel
nerv
hair
follicl
sweat
sebac
gland
found
subcutan
tissu
skin
sometim
refer
hypodermi
consist
primarili
fat
vari
wide
thick
differ
bodi
surfac
cours
individu
skin
thick
map
children
identifi
histolog
suitabl
site
cutan
vaccin
equal
import
select
skin
site
easili
access
minim
disrob
loss
privaci
smallpox
erad
volar
surfac
forearm
commonli
use
quickli
access
vaccin
could
hold
vaccine
wrist
stabil
prevent
escap
scar
easili
visibl
verifi
prior
vaccin
speed
diffus
therapeut
substanc
transcellularli
dead
live
keratinocyt
via
intercellular
channel
correl
smaller
molecul
da
lower
melt
point
increas
lipophil
correspondingli
lower
water
solubl
higher
satur
concentr
rel
lack
pendant
group
form
hydrogen
bond
slow
diffus
specif
mechan
produc
result
immun
respons
vaccin
antigen
introduc
skin
entir
clear
stimul
keratinocyt
produc
proinflammatori
cytokin
eg
interleukin
function
antigenpres
cell
display
major
histocompat
complex
mhc
class
ii
antigen
human
leukocyt
antigen
hla
dr
well
intercellular
adhes
molecul
epiderm
langerhan
cell
believ
play
key
role
cutan
immun
although
dermal
dendrit
cell
wellknown
immun
system
player
lymphocyt
mast
cell
macrophag
also
circul
resid
epidermi
dermi
immatur
langerhan
cell
resid
like
sentinel
among
keratinocyt
epidermi
compris
quarter
skin
surfac
area
effici
captur
foreign
antigen
phagocytosi
endocytosi
like
dendrit
cell
tissu
see
chapter
activ
see
figur
profession
antigenpres
cell
apc
process
antigen
migrat
drain
lymph
node
matur
express
high
level
class
ii
mhc
molecul
present
antigen
brought
skin
thelper
th
lymphocyt
critic
step
subsequ
immun
respons
orchestr
latter
cell
year
cutan
vaccin
smallpox
see
chapter
varieti
sharp
instrument
use
cut
scratch
poke
otherwis
penetr
epidermi
unnecessarili
deeper
dermi
inocul
cowpox
vaccinia
viru
figur
b
c
centuri
scarif
method
involv
scratch
one
line
skin
needl
scalpel
lancet
knife
rub
vaccin
result
lesion
rotari
lancet
first
describ
consist
shaft
attach
center
small
disk
opposit
patient
side
contain
central
tine
surround
smaller
satellit
tine
twirl
disk
drop
vaccin
skin
produc
much
abras
skin
often
sever
reaction
vaccin
common
bacteri
contamin
less
traumat
multiplepressur
method
introduc
earli
liquid
vaccin
place
onto
skin
straight
surgic
needl
held
tangenti
skin
tip
drop
repeatedli
firmli
press
sideway
limb
time
primari
vaccin
time
revaccin
multitin
devic
also
use
bifurc
needl
benjamin
rubin
invent
bifurc
needl
see
figur
wyeth
waiv
royalti
world
health
organ
could
produc
smallpox
erad
devic
hold
approxim
capillari
action
tine
appli
perpendicularli
skin
use
one
fifth
typic
dose
volum
need
earlier
multiplepressur
method
requir
higher
viru
concentr
simplic
portabl
economi
greatli
facilit
latter
half
smallpox
erad
particularli
asia
east
africa
bacil
vaccin
prevent
diseas
mycobacterium
tuberculosi
origin
administ
oral
see
chapter
safeti
concern
prompt
shift
cutan
administr
id
needl
inject
later
multipl
punctur
scarif
multitin
devic
figur
imag
c
g
f
describ
earlier
smallpox
vaccin
bcg
also
deliv
cutan
jet
injector
bifurc
needl
needl
techniqu
classic
intraderm
inject
use
bcg
develop
earli
centuri
felix
mendel
separ
charl
mantoux
administr
tuberculin
replac
purifi
protein
deriv
use
diagnosi
tuberculosi
infect
refer
mantoux
method
procedur
becom
common
rout
id
inject
variou
antigen
see
figur
shortbevel
finegaug
needl
usual
gaug
inch
mm
diamet
insert
bevel
angl
slightli
stretch
skin
often
volar
surfac
forearm
tip
advanc
mm
entir
bevel
cover
upon
inject
fluid
proper
locat
bevel
dermi
creat
bleb
wheal
basement
membran
epidermi
stretch
fluid
leakag
onto
skin
indic
insuffici
penetr
cover
bevel
failur
produc
bleb
indic
improperli
deep
locat
fluid
subcutan
tissu
drawback
mantoux
method
mass
vaccin
campaign
train
skill
extra
time
need
accomplish
correctli
potenti
dosagespar
effect
id
vaccin
reduc
amount
antigen
need
reduc
volum
ml
prompt
renew
attent
rout
concern
emerg
threat
pandem
influenza
sever
acut
respiratori
syndrom
sar
bioterror
may
leav
popul
vulner
insuffici
vaccin
suppli
old
new
techniqu
easili
achiev
classic
intraderm
inject
mantoux
method
deposit
inject
skin
produc
rais
bleb
wheal
temporari
indur
sinc
multiusenozzl
jet
injector
see
jet
inject
later
allow
id
deliveri
smallpox
bcg
vaccin
use
special
nozzl
see
figur
adapt
modern
disposablesyring
jet
injector
technolog
also
achiev
classic
intraderm
inject
name
tropi
bioject
idpen
see
figur
k
circumv
amount
skill
time
need
success
mantoux
inject
becton
dickinson
bd
develop
prefil
glass
syring
stake
outer
diamet
od
mm
minineedl
project
mm
beyond
depthlimit
hub
intuit
perpendicular
insert
skin
see
figur
term
soluvia
microdeliveri
system
licens
exclus
sanofi
pasteur
certain
vaccin
applic
soluvia
first
major
clinic
trial
although
unidentifi
public
id
trial
arm
use
investig
glaxosmithklin
gsk
influenza
vaccin
later
sanofi
pasteur
undertook
seri
clinic
trial
trival
inactiv
influenza
vaccin
led
market
approv
europ
id
deliveri
intanza
idflu
product
contain
either
g
viral
hemagglutinin
per
strain
per
ml
adult
age
full
nondosag
spare
g
older
us
trial
cite
product
insert
sanofi
pasteur
usmad
fluzon
intraderm
product
contain
g
per
strain
found
induc
geometr
mean
titer
gmt
hemagglutinationinhibit
antibodi
noninferior
control
patient
receiv
convent
fluzon
im
rout
g
per
strain
us
food
drug
administr
fda
licens
vaccin
uniqu
prefil
deliveri
system
indic
use
patient
year
age
sever
countri
eg
stake
minineedl
project
mm
beyond
hub
limit
depth
inject
upon
perpendicular
insert
skin
market
vaccinedevic
combin
product
approv
european
union
unit
state
investig
adaptor
convent
tuberculin
syringeneedl
quick
consist
mantoux
intraderm
inject
sid
technolog
west
path
use
rabi
vaccin
develop
world
among
indic
fix
gap
mm
underneath
skitip
guid
manipul
skin
optim
needl
placement
regardless
bevel
orient
j
investig
new
version
tropi
needlefre
intraderm
jet
injector
pharmajet
j
inset
unfold
cock
wing
use
compress
metal
spring
inject
origin
model
clear
fda
us
market
k
investig
bioject
id
pen
needlefre
jet
injector
intraderm
deliveri
ml
model
shown
bioject
medic
technolog
power
metal
spring
cock
builtin
lever
dispos
polypropylen
spacer
dispos
syring
creat
desir
air
gap
weaken
jet
stream
intraderm
deliveri
canada
australia
new
zealand
also
licens
sanofi
influenza
vaccin
soluvia
minineedl
deliveri
system
plastic
nonprefil
empti
steril
version
soluvia
minineedl
syring
potenti
avail
other
endus
fill
detach
hub
expos
full
needl
length
access
convent
vial
potenti
applic
includ
postexposur
rabi
prophylaxi
develop
world
clinic
trial
demonstr
protect
seroconvers
compar
full
dosag
im
rout
see
convent
vaccin
later
well
deliveri
proteinbas
therapeut
among
other
od
mm
version
soluvia
without
bulki
plastic
emballag
requir
shield
needl
health
worker
size
preclin
anim
experi
produc
good
immun
respons
anthrax
recombin
protect
antigen
rpa
convent
hemagglutinin
plasmid
dna
antigen
influenza
live
recombin
yellow
fever
vector
japanes
enceph
vaccin
rabbit
immun
intraderm
challeng
ld
bacillu
anthraci
spore
surviv
rate
adjuv
aluminum
salt
adjuv
alum
cpg
ident
imimmun
control
rhesu
macaqu
protect
aerosol
challeng
lethal
dosag
anthrax
botul
plagu
staphylococc
pathogen
toxin
novel
syring
adapt
see
figur
design
quicker
insert
improv
consist
tradit
mantoux
techniqu
see
figur
guid
needl
appropri
posit
skin
produc
desir
bleb
human
trial
conduct
path
known
program
appropri
technolog
health
adapt
luer
interfac
fit
convent
syring
inject
ml
produc
desir
bleb
bevelup
beveldown
inject
yield
mean
diamet
mm
mm
sd
rang
mm
id
deposit
confirm
ultrasound
patient
devic
develop
sid
technolog
financi
technic
support
center
diseas
control
prevent
cdc
west
pharmaceut
servic
path
right
develop
world
rabi
vaccin
applic
licensur
west
manufactur
market
adapt
unit
state
develop
countri
addit
smallpox
bcg
combin
bcgandsmallpox
vaccin
dozen
vaccin
type
administ
intraderm
substanti
literatur
document
equival
immunogen
occasion
superior
less
commonli
lower
respons
influenza
vaccin
id
rout
use
needlesyring
compar
larger
dosag
sc
im
rout
studi
took
place
two
era
first
start
report
thoma
franci
salk
polio
vaccin
trial
fame
extend
last
two
season
influenza
anew
swine
flu
paper
publish
indic
equival
superior
sampl
size
analyt
rigor
modern
clinic
trial
six
studi
found
id
rout
less
immunogen
sc
im
rout
antigen
studi
attempt
dosag
spare
id
rout
compar
either
im
sc
rout
use
ident
amount
reduc
antigen
result
conflict
midcenturi
trial
use
wholecel
product
era
bruyn
colleagu
found
gmt
children
receiv
ml
intraderm
influenza
vaccin
higher
receiv
dosag
subcutan
davi
cowork
tauraso
colleagu
administ
ml
rout
administ
id
rout
onetenth
ml
sc
dose
ml
vari
dilut
label
dosag
chick
cell
agglutin
cca
unitsml
still
cowork
also
found
greater
id
respons
sc
dosag
low
cca
id
dosag
respect
contrast
sc
respons
exceed
id
one
standard
sc
dosag
use
reduc
one
log
cca
id
cca
respect
suggest
linear
id
dosagerespons
curv
sigmoid
sc
one
favor
id
rout
lowerdosag
end
hand
ident
reduc
dosag
new
shift
asian
strain
given
two
rout
cca
compar
per
full
ml
mccarrol
colleagu
studi
hospit
employe
year
age
klein
cowork
studi
infant
month
year
age
found
littl
differ
respons
id
sc
rout
mccarrol
specul
id
superior
earlier
studi
result
anamnest
effect
present
season
klein
simpli
doubt
id
superior
equal
volum
use
regard
system
reaction
among
infant
month
year
age
receiv
ml
influenza
vaccin
studi
klein
huang
febril
reaction
report
among
intraderm
group
sc
group
get
reduc
dosag
similarli
local
reaction
small
area
erythema
indur
slight
tender
itch
within
day
describ
intraderm
particip
age
month
year
n
wherea
children
vaccin
sc
rout
local
pain
indur
consid
entir
reduceddosag
id
influenza
literatur
rout
might
consid
antigen
shortag
distribut
equiti
demand
use
lower
end
dosagerespons
curv
id
may
outperform
sc
im
rout
increas
reaction
describ
wholeviru
studi
would
perhap
mitig
use
today
less
reactogen
splitviru
product
twentyf
year
final
id
influenza
studi
two
paper
publish
simultan
soon
sever
nation
shortag
reviv
interest
dosag
spare
among
hit
literatur
search
may
intraderm
influenza
vaccin
studi
publish
sinc
young
marra
cull
report
nonseason
vaccin
avian
pandem
duplic
otherwis
inappropri
remain
exclud
either
anim
studi
nonrandom
use
obsolet
wholeviru
antigen
assess
immun
outsid
select
window
day
vaccin
comprehens
compar
remain
report
splitviru
studi
onward
among
adult
year
age
older
report
young
marra
found
dosag
smaller
id
rout
studi
compar
immunogen
full
dosag
given
intramuscularli
seven
eight
age
rang
four
six
trial
among
older
year
id
superior
found
without
dosag
spare
remain
two
studi
older
group
usual
local
reaction
consist
frequent
id
rout
among
publish
id
influenza
studi
includ
young
marra
review
studi
children
hong
kong
given
season
trival
vaccin
fluarix
gsk
found
ml
id
dosag
compar
immunogen
full
im
one
increas
toler
indur
erythema
id
deliveri
anoth
studi
texa
administ
investig
monoval
avian
antigen
adult
dosag
id
rout
im
rout
dosag
less
g
either
rout
induc
poor
respons
wherea
g
im
rout
induc
fourfold
titer
rise
titer
greater
two
dose
one
multicent
studi
encompass
rang
four
dosag
hemagglutinin
per
vaccin
strain
formul
fluzon
compar
g
im
needl
g
intraderm
soluvia
minineedl
syring
g
mantoux
inject
gmt
g
id
dose
noninferior
im
control
three
strain
g
id
dose
noninferior
strain
studi
fluzon
id
vaccin
deliv
soluvia
minineedl
describ
see
reinvent
wheal
earlier
lowdosag
id
vaccin
compar
fulldosag
im
rout
ascertain
whether
low
dosag
muscl
usual
fewer
local
reaction
would
perform
well
belsh
colleagu
address
question
ad
third
arm
trial
lowdosag
influenza
vaccin
tradit
mantoux
inject
id
rout
versu
control
found
low
dosag
either
id
im
rout
almost
immunogen
fulldosag
im
control
salk
first
clinic
trial
inactiv
polio
vaccin
administ
id
rout
routin
use
million
dane
mid
respons
studi
good
earli
polio
erad
near
goal
necessari
remov
circul
live
sabin
strain
oral
polio
vaccin
opv
propens
revert
virul
circul
vaccine
other
replac
inject
inactiv
polio
vaccin
ipv
howev
latter
vaccin
full
dosag
cost
time
much
per
dose
opv
promot
search
costsav
strategi
also
avoid
introduct
needl
polio
erad
program
recent
clinic
research
oman
sponsor
other
found
seroconvers
rate
equival
full
dosag
given
intramuscularli
ipv
deliv
intraderm
needlefre
jet
injector
ml
dosagespar
volum
skin
infant
month
age
gmt
consist
lower
earlier
age
week
studi
cuba
id
respons
somewhat
lower
perhap
matern
antibodi
interfer
studi
philippin
compar
onefifth
dosag
mantoux
inject
full
dosag
im
rout
week
age
find
invers
titer
greater
three
type
particip
conclud
reduceddosag
id
rout
noninferior
im
rout
indian
studi
older
children
month
age
use
differ
investig
jet
injector
id
deliveri
deem
half
inject
inadequ
wheal
diamet
less
mm
small
drop
vaccin
remain
skin
surfac
overal
seroconvers
rate
gmt
polio
type
lower
reduceddosag
id
rout
full
im
dosag
especi
inadequ
inject
anoth
studi
netherland
devic
underway
plan
id
rout
use
extens
live
attenu
yellow
fever
french
neurotrop
vaccin
given
id
scarif
francophon
africa
see
chapter
strain
show
good
poor
immun
respons
jetinject
id
rout
recent
review
discuss
evid
dosagespar
equival
skin
use
onefifth
usual
dosag
inactiv
vaccin
good
immun
respons
id
inject
includ
typhoid
rabi
latter
use
wide
dosagespar
purpos
develop
world
gener
good
result
report
id
hepat
b
except
antigen
mass
prepar
reduct
instead
common
reduct
id
rout
infant
recombin
vaccin
recent
metaanalysi
among
five
compar
random
clinic
trial
total
subject
publish
studi
found
slight
decrement
seroprotect
rate
hepat
b
id
rout
compar
im
rout
contrast
anoth
metaanalysi
found
hepat
b
id
rout
somewhat
immunogen
im
rout
among
dialysi
patient
meningococc
diseas
one
paper
group
vaccin
mid
late
id
rout
pursu
wide
varieti
investig
vaccin
includ
dengu
human
immunodefici
viru
hiv
malaria
tuberculosi
id
routea
well
imhad
led
serendipit
discoveri
influenza
model
viral
gene
encod
bacteri
dna
could
express
protein
antigen
vivo
semin
event
modern
era
recombin
nucleic
acid
vaccinolog
gene
protoantigen
prevent
influenza
hiv
acquir
immunodefici
syndrom
aid
smallpox
mani
diseas
insert
nake
dnarna
variou
vector
modifi
vaccinia
ankara
viru
deliveri
id
rout
id
jet
inject
use
immunomodul
interferon
novel
method
deliv
antigen
skin
variou
commerci
patch
deliveri
system
develop
sinc
demonstr
abil
certain
therapeut
agent
eg
scopolamin
nitroglycerin
clonidin
estradiol
fentanyl
nicotin
testosteron
diffus
passiv
bare
untreat
skin
without
use
activ
technolog
enhanc
describ
follow
paragraph
howev
passiv
diffus
usual
work
small
molecul
certain
physic
characterist
thu
anim
model
immun
onto
bare
untreat
skin
newer
method
facilit
antigen
deliveri
epidermi
involv
painlessli
strip
abrad
scrape
pierc
vapor
shock
vibrat
bombard
otherwis
permeabil
barrier
stratum
corneum
method
combin
sever
process
detail
review
other
strip
abrad
tape
friction
varieti
simpl
tool
use
remov
stratum
corneum
common
cellophan
adhes
tape
may
appli
skin
pull
away
carri
away
dead
keratinocyt
repetit
tapestrip
shown
enhanc
cytotoxictcel
cytokin
immun
respons
subsequ
applic
variou
antigen
adjuv
skin
mice
similarli
rub
gauz
emeri
paper
electrocardiograph
ecg
pad
pumic
skin
remov
cell
abras
effect
found
enhanc
immun
respons
human
applic
cyanoacryl
glue
follow
strip
skin
appli
antigen
expos
hair
follicl
describ
practic
question
among
method
strip
skin
perhap
advanc
one
combin
step
use
remark
potent
adjuv
heatlabil
enterotoxin
lt
escherichia
coli
see
bacteri
exotoxin
later
effort
origin
champion
gregori
glenn
first
walter
reed
armi
institut
research
iomai
corpor
later
intercel
vaccin
patient
hold
skin
devic
skin
prepar
system
develop
ideo
figur
push
button
pull
tab
control
pressur
appli
sandpap
strip
gentli
abrad
remov
stratum
corneum
patch
contain
lt
antigen
alon
contain
lt
adjuv
anoth
antigen
appli
skin
process
call
transcutan
immun
lt
alon
intend
induc
immun
enterotoxigen
e
coli
etec
caus
travel
diarrhea
vibrio
cholera
without
etec
colon
factor
initi
random
blind
field
trial
among
travel
guatemala
mexico
found
efficaci
patch
lt
alon
protect
moder
sever
diarrhea
intercel
report
mix
result
two
followup
field
studi
pivot
phase
trial
travel
diarrhea
n
guatemala
mexico
trial
primari
target
endpoint
greater
efficaci
moder
sever
etec
diarrhea
met
find
protect
effect
frequenc
caus
diarrhea
howev
reduct
incid
ltposit
diarrhea
degre
sever
along
signific
reduct
durat
sever
diarrhea
caus
patch
also
induc
measur
immun
respons
well
toler
smaller
phase
trial
india
n
lt
patch
also
reach
target
endpoint
perhap
low
attack
rate
ltposit
etec
result
two
trial
intercel
discontinu
work
lt
patch
travel
diarrhea
still
pursu
use
skin
prepar
system
devic
applic
appli
intercel
lt
patch
near
site
inject
parenter
influenza
vaccin
applic
refer
vaccineenhanc
patch
found
improv
hemagglutin
inhibit
hi
titer
serum
mucosa
young
age
mice
increas
hi
titer
show
improv
trend
adult
volunt
older
year
may
partnership
intercel
gsk
began
enrol
volunt
studi
compar
patch
adjuv
boost
respons
pandem
influenza
vaccin
preclin
studi
applic
use
lt
structur
similar
cholera
toxin
cutan
adjuv
result
improv
immun
respons
challeng
protect
anim
model
tetanu
anthrax
malaria
helicobact
pylori
shiga
toxinproduc
strain
enterohemorrhag
e
coli
regard
safeti
earli
clinic
trial
found
seriou
reaction
pruritu
maculopapular
rash
patch
site
found
patient
expos
ltcontain
patch
hour
one
studi
rash
progress
vesicl
format
delayedtyp
hypersensit
contact
dermat
observ
use
recombin
colon
factor
later
clinic
trial
found
lt
patch
well
toler
consist
previou
studi
microrasp
method
take
advantag
lowcost
fabric
techniqu
adapt
microelectron
industri
convert
silicon
metal
materi
array
micrometerto
millimeters
microrasp
design
abrad
stratum
corneum
distinct
creat
hole
see
poke
pierc
later
one
exampl
microenhanc
array
mea
also
known
onvax
investig
technolog
scrape
skin
topic
applic
antigen
therapeut
agent
mea
consist
squar
round
chip
contain
area
silicon
plastic
microproject
mount
fingerheld
applic
preclin
studi
mea
devic
use
mice
inocul
hepat
b
surfac
antigen
hbsag
dna
plasmid
encod
firefli
luciferas
found
similar
greater
immun
respons
light
emiss
respect
compar
control
im
experiment
id
inject
anthrax
rpa
alum
cpg
adjuv
appli
mea
devic
mous
skin
produc
equival
better
immun
respons
im
control
although
good
id
microneedl
wherea
immun
respons
challeng
surviv
significantli
less
among
meaimmun
rabbit
compar
im
control
among
cynomolgu
monkey
vaccin
six
swipe
mea
sc
microneedlebas
id
control
anim
seroconvert
investig
recombin
japanes
enceph
vaccin
vaccin
swipe
mea
drop
vaccin
alreadi
skin
show
neutral
antibodi
respons
rang
sc
control
wherea
appli
vaccin
abras
appear
less
effect
clinic
trial
mea
measur
transepiderm
water
loss
tewl
surrog
indic
remov
stratum
corneum
five
consecut
swipe
across
site
volar
forearm
volunt
project
height
show
steadili
increas
rate
tewl
tallest
project
produc
greatest
water
loss
control
swipe
fibrou
sandpap
ecg
pad
show
littl
tewl
human
trial
howev
rabi
vaccin
appli
four
rub
devic
four
separ
deltoid
skin
site
detect
immun
respons
three
dose
day
razor
brush
also
remov
layer
stratum
corneum
clinic
trial
adenoviru
vector
encod
express
influenza
hemagglutinin
antigen
abdomin
skin
adult
shave
dispos
twinblad
razor
follow
gentl
brush
softbristl
toothbrush
stroke
applic
antigen
occlus
tegaderm
patch
two
dose
day
apart
highest
dosag
level
produc
fourfold
rise
hi
titer
cutan
vaccin
control
group
receiv
convent
parenter
deliveri
either
recombin
vaccin
vector
licens
inactiv
influenza
vaccin
occasion
mild
erythema
abdomin
site
report
rash
itch
patient
research
team
studi
mice
substitut
electr
trimmer
shave
otherwis
use
similar
brush
demonstr
topic
applic
nonrepl
e
coli
vector
overproduc
antigen
clostridium
tetani
b
anthraci
immunogen
control
anim
demonstr
depil
alon
littl
effect
made
differ
mild
brush
produc
minim
irrit
draiz
score
other
studi
japanes
enceph
vaccin
anim
model
supplement
skin
shave
commerci
depilatori
cream
follow
occlus
site
imperm
cover
practic
step
routin
immun
human
uncertain
cutan
vaccin
gener
divers
terminolog
appli
microscop
project
perfor
superfici
skin
deliv
drug
addit
common
term
microneedl
term
microblad
microkn
micropin
microtin
microtub
nanopatch
use
chapter
use
microneedl
broad
categori
project
shorter
reserv
minineedl
mm
longer
whether
solid
hollow
see
minineedl
microrasp
earlier
follow
section
divid
microneedl
function
subcategori
earlier
describ
method
vaccin
drug
appli
site
prepar
corpor
develop
uncoat
microneedl
devic
prepar
skin
perfor
although
licens
even
intend
vaccin
drug
microchannel
skin
system
microneedl
appear
us
market
pretreat
method
profession
medic
cosmet
dermatologist
creat
microchannel
skin
see
figur
applic
creat
hole
stratum
corneum
epidermi
investig
technolog
uncoat
microneedl
microcor
function
microarray
patch
microtran
common
strategi
pursu
number
commerci
academ
team
carri
antigen
across
stratum
corneum
coat
onto
solid
microscop
project
held
variabl
period
time
epiderm
layer
antigen
drug
elut
diffus
date
limit
publish
data
demonstr
suitabl
human
vaccin
contrast
therapeut
drug
one
exampl
drugcoat
microneedl
appear
closest
market
approv
investig
zosano
pharma
zp
patch
platform
formerli
known
macroflux
see
figur
titanium
project
vari
height
pack
area
cm
densiti
tine
per
squar
centimet
insert
springmount
applic
held
place
adhes
patch
advanc
applic
microneedl
deliveri
parathyroid
hormon
treat
osteoporosi
alreadi
studi
clinic
erythropoietin
treat
anemia
regard
vaccin
applic
graph
human
studi
zosano
pharma
zpflu
influenza
vaccin
patch
appli
minut
onto
skin
trend
toward
increas
titer
seroprotect
compar
im
control
inject
detail
provid
could
public
clinic
trial
registr
found
hairless
guinea
pig
model
use
studi
ovalbumin
patch
microneedl
repres
larg
antigen
protein
administ
two
dose
week
apart
induc
postboost
titer
compar
control
im
sc
id
mantouxstyl
inject
higher
dosag
surpass
im
sc
rout
lower
dosag
preclin
studi
system
demonstr
deliveri
oligonucleotid
peptid
hormon
desmopressin
compani
report
anim
work
tetanu
diphtheria
lyme
diseas
hepat
b
dna
vaccin
antigen
anoth
coatedmicroneedl
platform
solid
mictrostructur
transderm
system
smt
drugcoat
pyramid
project
vari
height
array
microneedl
mount
adhes
patch
densiti
per
squar
centimet
applic
skin
manual
fingerthumb
press
patch
devic
see
figur
springpow
applic
shown
elsewher
coat
microneedl
said
hold
mg
activ
pharmaceut
ingredi
rabbit
model
coat
tetanu
toxoid
alum
adjuv
variou
ratio
induc
antibodi
level
order
magnitud
higher
presum
protect
threshold
iu
use
fraction
standard
im
dosag
ovalbumin
surrog
vaccin
appli
hairless
guinea
pig
smt
use
press
patch
applic
report
induc
antibodi
measur
enzymelink
immunosorb
assay
equival
induc
imneedl
inject
second
studi
use
hairless
guinea
pig
compar
three
dose
hbsag
smt
id
im
inject
week
two
dose
seroconvers
gmt
id
rout
gmt
im
rout
dose
seroconvers
im
rose
gmt
id
rout
remain
gmt
rose
swine
model
viruslik
protein
hbsag
demonstr
dosag
spare
via
smt
compar
antigen
deliv
im
control
rout
experiment
placement
smt
microneedl
devic
human
volunt
found
welltoler
nonintimid
pain
recent
public
registr
describ
safeti
trial
without
antigen
otherwis
clinic
data
found
public
registri
report
georgia
institut
technolog
ga
tech
pioneer
center
microneedl
technolog
work
emori
univers
conduct
numer
studi
coat
microneedl
anim
model
cutan
vaccin
deliveri
seri
murin
studi
use
solid
metal
microneedl
coat
inactiv
influenza
virus
cutan
vaccin
induc
robust
immun
responsesoften
better
equival
dosag
control
inject
sc
routea
well
protect
lethal
viral
challeng
coat
bcg
microneedl
platform
see
figur
highli
immunogen
guinea
pig
robust
cellmedi
respons
lung
spleen
compar
mantoux
inject
similarli
plasmid
dna
antigen
hepat
c
coat
needl
prime
specif
cytotox
lymphocyt
vaccin
mice
readili
typic
gene
gun
deliveri
convent
needl
inactiv
rotaviru
vaccinedevelop
avoid
inhibitori
effect
breast
milk
live
oral
vaccin
coat
onto
microneedl
platform
found
immunogen
anim
model
formul
prepar
ga
tech
key
ingredi
carboxycellulos
matrix
dri
coat
trehalos
one
sever
sugar
includ
sucros
found
use
protect
protein
antigen
damag
dri
freez
therebi
improv
vaccin
thermost
anoth
center
microneedl
research
australia
develop
novel
nitrogen
ga
jetdri
method
coat
antigen
onto
silicon
overcom
challeng
dipcoat
close
space
project
still
elut
within
minut
upon
skin
entri
see
figur
achiev
dosag
spare
compar
im
rout
mous
model
influenza
antigen
studi
good
result
murin
model
platformcal
nanopatch
recent
transfer
industri
includ
human
papillomaviru
herp
simplex
type
west
nile
chikungunya
virus
coulman
cowork
studi
nanoparticl
dna
plasmid
express
fluoresc
protein
appli
epiderm
surfac
ex
vivo
human
breast
skin
donat
mastectomi
appli
microneedl
skin
second
abl
verifi
epiderm
penetr
gene
express
varieti
histolog
photometr
mean
later
work
welsh
group
report
decreas
pain
clinic
studi
microneedl
compar
convent
needl
well
morpholog
chang
suggest
immun
activ
human
langerhan
cell
intraderm
inject
influenza
viruslik
particl
excis
human
skin
group
also
found
public
privat
immun
provid
posit
focusgroup
discuss
toward
microneedl
chang
convent
needlesyring
deliveri
research
develop
coat
microneedl
vaccin
also
underway
mani
group
eleg
strategi
decreas
risk
intent
reus
inadvert
contact
use
microneedl
sharp
dissolv
skin
hydrat
thu
releas
antigen
common
matrix
dissolv
microneedl
hard
enough
penetr
skin
carboxymethylcellulos
gener
recogn
safe
parenter
deliveri
fda
among
compound
chu
prausnitz
mold
arrowheadshap
antigen
carrier
blend
polyvinyl
alcohol
polyvinylpyrrolidon
mount
metal
shaft
figur
lower
corner
arrow
act
barb
keep
carrier
skin
patch
remov
done
immedi
group
ga
tech
emori
sullivan
cowork
encapsul
inactiv
influenza
vaccin
viru
biocompat
polym
dissolv
within
minut
applic
mous
skin
see
figur
robust
antibodi
cellular
immun
respons
provid
complet
protect
lethal
challeng
sever
sugar
trehalos
sucros
maltos
found
key
ingredi
stabil
maintain
potenc
antigen
process
form
dissolv
microneedl
thermost
studi
yet
report
assess
whether
formul
would
resist
heat
degrad
allow
transport
storag
outsid
cold
chain
hydrogel
polym
propos
corium
intern
bindercumadhes
activ
pharmaceut
ingredi
dissolv
deliveri
skin
japan
cosm
market
cosmet
microhyala
microneedl
array
contain
hyaluron
dissolv
minut
vaccin
applic
plan
mani
other
also
pursu
dissolv
microneedl
hollow
microproject
similar
submillimet
length
solid
one
describ
design
inject
therapeut
liquid
tini
lumen
chapter
needl
less
mm
long
classifi
microneedl
oppos
stillsmal
longer
minineedl
soluvia
system
see
figur
see
reinvent
wheal
earlier
although
harder
manufactur
easili
broken
clog
flow
rate
microneedl
measur
remark
ml
per
minut
per
cannula
common
length
short
enough
theori
painless
would
reach
nerv
end
dermi
howev
quit
percept
stretch
skin
inject
liquid
may
elimin
advantag
micronjet
devic
uniqu
avail
licens
steril
dispos
devic
end
user
inject
liquid
wearabl
devic
fix
adhes
skin
activ
prefil
liquid
drug
forc
minut
lumina
e
bottom
center
microneedl
e
bottom
right
height
blue
button
e
upper
right
schemat
releas
spring
c
trigger
pierc
glass
dose
chamber
b
transfer
liquid
reservoir
patch
appli
skin
deliveri
spring
f
held
place
adhes
cutan
deliveri
consist
three
hollow
microneedl
bevel
pyramid
shape
mount
adapt
luer
interfac
fit
onto
convent
syring
liquid
vaccin
drug
see
figur
clear
fda
inject
drug
approv
id
deliveri
also
hold
ce
mark
market
europ
adult
volunt
vaccin
intraderm
similar
micronjet
version
four
microneedl
height
receiv
reduc
singl
dose
full
dose
im
rout
licens
alpharix
fluarix
gsk
season
influenza
vaccin
day
three
studi
arm
develop
compar
increas
gmt
satisfi
european
criteria
relicensur
season
influenza
vaccin
full
local
reaction
frequent
im
rout
mild
transient
similar
dosagespar
trial
monoval
influenza
vaccin
trival
vaccin
confirm
compar
superior
immun
respons
id
rout
versu
im
anoth
hollow
microneedl
system
hollow
microstructur
transderm
system
hmt
patientcontact
surfac
contain
microneedl
length
whose
lumina
diamet
deliv
liquid
volum
rang
ml
see
figur
springpow
devic
contain
liquid
drug
prefil
glass
dose
chamber
upon
trigger
stopper
chamber
pierc
spike
dose
pass
forc
slowli
period
minut
microneedl
skin
upper
arm
thigh
adhes
patch
keep
system
place
deliveri
complet
deliveri
equin
tetanu
antitoxin
swine
model
deliveri
monoclon
antibodi
result
pharmacokinet
profil
tetanu
antitoxin
similar
dosag
via
sc
inject
group
also
pursu
hollow
microneedl
preclin
studi
use
commerci
cosmet
tattoo
machin
deliv
experiment
dna
vaccin
antigen
multineedl
array
eg
nine
vibrat
frequenc
hz
durat
second
result
thousand
ten
thousand
skin
pierc
per
dose
whether
potenti
pain
deliveri
method
would
practic
econom
esthet
accept
human
vaccin
well
advantag
method
cutan
deliveri
remain
demonstr
use
light
electr
heat
radiat
produc
pursu
facilit
entri
drug
skin
either
brief
constant
applic
energi
pathway
creat
short
puls
laser
light
use
variou
way
breach
stratum
corneum
one
techniqu
brief
puls
ablat
layer
drug
appli
directli
onto
expos
epidermi
often
occlus
patch
hour
stratum
regener
lad
laserassist
drug
deliveri
devic
gener
erbiumdop
yttriumaluminumgarnet
yag
laser
beam
whose
energi
highli
absorb
skin
shown
adult
volunt
facilit
anesthet
effect
topic
applic
lidocain
licens
unit
state
australia
purpos
new
system
focus
laser
beam
creat
pore
per
activ
claim
pore
diamet
select
depth
remain
epidermi
reach
dermal
nerv
end
anoth
method
use
highpow
puls
laser
creat
photomechan
wave
drive
particl
repres
drug
carrier
stratum
corneum
clinic
studi
intend
vaccin
use
laser
method
yet
report
iontophoresisfirst
demonstr
centuri
ago
rabbit
electr
current
drive
charg
molecul
electrod
charg
toward
anoth
opposit
charg
locat
elsewher
bodi
licens
devic
appli
techniqu
skin
anesthesia
relat
method
electroosmosi
induc
flow
solvent
carri
uncharg
molecul
voltag
greater
volt
increas
skin
permeabl
perhap
open
pathway
along
hair
follicl
techniqu
work
well
larger
molecul
character
mani
vaccin
antigen
protein
thermopor
also
term
micropor
use
heat
vapor
tini
open
stratum
corneum
passport
system
heat
gener
dispos
array
metal
filament
held
momentarili
skin
devic
size
comput
mous
see
figur
activ
electr
puls
induc
heat
filament
adhes
patch
contain
vaccin
therapeut
agent
appli
micropor
creat
hairless
mous
model
techniqu
elicit
greater
cellular
humor
respons
adenoviru
vaccin
intact
skin
well
protect
surrog
tumor
challeng
intact
skin
model
adenovirusvector
melanoma
antigen
appli
micropor
roughli
doubl
averag
onset
time
tumor
challeng
protect
one
six
mice
compar
none
eight
vaccin
control
intact
skin
micropor
recombin
influenza
hemagglutinin
protect
balbc
mice
challeng
lethal
strain
skin
micropor
also
permit
passag
insulin
pharmacokinet
human
trial
histor
control
direct
allow
interstiti
fluid
extract
potenti
glucos
monitor
anoth
devic
similarli
gener
micropor
heat
induc
radiofrequ
wave
viaderm
differ
techniqu
use
short
puls
superh
steam
microlit
amount
remov
stratum
corneum
without
appar
effect
deeper
skin
element
human
cadav
model
result
vitro
increas
permeabl
sulforhodamin
b
bovin
serum
albumin
surrog
molecul
drug
antigen
electropor
use
short
electr
puls
produc
intercellular
lipid
matrix
stratum
corneum
temporari
pore
nanometerrang
diamet
remain
open
permeabl
hour
vitro
vivo
preclin
studi
techniqu
demonstr
skin
entri
larger
molecul
heparin
kda
peptid
protein
luteinizinghormonereleas
hormon
nucleic
acid
potenti
extens
use
investig
dna
vaccin
anim
human
easi
vax
relat
derma
vax
epiderm
electropor
system
combin
applic
antigen
drugcoat
minineedl
follow
electropor
smallpox
antigen
plasmid
dna
dri
onto
tip
array
insert
skin
mice
follow
six
electr
puls
induc
protect
smallpox
challeng
prostat
cancer
dna
vaccin
similarli
administ
electropor
im
rout
also
pursu
enhanc
vaccin
dna
antigen
facilit
drug
antigen
deliveri
connect
keratinocyt
solubil
ultrason
wave
shortdur
shock
wave
theoriz
induc
cavitationth
format
collaps
microbubbleswhich
disrupt
intercellular
bilay
stratum
corneum
low
frequenc
khz
appear
work
better
higher
frequenc
use
therapeut
ultrasound
mhz
transderm
tetanu
toxoid
immun
mice
enhanc
compar
sc
rout
subject
ultrasound
khz
highmolecularweight
molecul
deliv
includ
insulin
erythropoietin
interferon
lowmolecularweight
heparin
variou
group
pursu
ultrasound
enhanc
drug
deliveri
transfect
cell
kinet
method
deposit
dnacoat
gold
particl
pioneer
helio
pd
gene
gun
accel
injector
becom
standard
bench
tool
biolist
deliveri
nucleic
acid
plasmid
wide
varieti
plant
anim
transfect
express
code
gene
deliveri
dna
skin
overcom
usual
polar
thelper
cell
type
respons
dna
deliv
muscl
devic
unavail
human
vaccin
patent
right
held
powderm
document
safeti
dna
antigen
rout
remain
major
regulatori
obstacl
paradigm
shift
human
vaccin
proprietari
term
epiderm
powder
immun
epi
particlemedi
epiderm
deliveri
pmed
refer
use
helium
ga
blow
powder
protein
polysaccharid
inactiv
pathogen
epi
dnacoat
particl
pmed
epidermi
superson
speed
uniqu
method
vaccin
develop
earli
oxford
bioscienc
year
renam
powderject
acquir
chiron
spun
powderm
final
acquir
pfizer
deliveri
either
reusabl
xr
seri
singleus
dispos
nd
seri
devic
see
figur
latter
target
commerci
convent
protein
antigen
deliveri
epi
spraydri
powder
suitabl
densiti
size
econom
manufactur
formul
may
obstacl
dna
vaccin
deliv
pmed
plasmid
code
desir
antigen
coat
onto
gold
bead
diamet
deposit
epiderm
antigenpres
cell
elut
transcrib
number
preclin
studi
variou
anim
model
conduct
human
trial
dna
vaccin
contain
one
order
magnitud
less
antigen
amount
use
im
rout
induc
humor
cellular
immun
respons
hepat
b
subject
previous
vaccin
convent
vaccin
pmed
vaccin
also
studi
dna
prime
trial
malaria
vaccin
produc
seroprotect
immun
respons
dna
vaccin
season
strain
influenza
reduc
influenza
symptom
viral
shed
human
challeng
clinic
trial
still
ongo
unpublish
studi
antigen
avian
influenza
dna
herp
simplex
viru
hiv
nonsmal
cell
lung
cancer
hepat
b
influenza
trial
cite
earlier
sever
local
reaction
erythema
swell
flake
crust
format
occur
nearli
subject
albeit
resolv
day
skin
discolor
howev
persist
day
subject
day
inject
site
beyond
month
patient
longterm
followup
antidoublestrand
dna
antibodi
detect
deposit
gold
particl
studi
pig
deposit
stratum
corneum
epidermi
eventu
slough
exfoli
day
day
administr
particl
remain
basal
epiderm
layer
macrophag
dermi
region
lymph
node
kinet
thermal
method
anoth
deliveri
method
term
needlefre
solid
dose
injector
sdi
british
firm
glide
pharma
see
figur
use
springload
devic
quickli
push
sc
tissu
sharp
point
biodegrad
pioneer
tip
solid
semisolid
medic
behind
chamberboth
width
grain
rice
microsciss
involv
stream
ga
contain
tini
crystal
inert
aluminum
oxid
bombard
small
area
skin
mask
skin
limit
sandblast
effect
narrow
area
channel
creat
stratum
corneum
drug
appli
anoth
method
use
fast
power
contractil
fiberactiv
pump
fire
drug
skin
suffici
veloc
penetr
epidermi
miniatur
form
tradit
jet
inject
use
piezoelectr
transduc
propel
liquid
microjet
skin
bather
notic
fingertip
prolong
wet
skin
occlud
hold
bodi
moistur
produc
fluid
accumul
intercellular
space
swell
keratinocyt
permit
enhanc
passag
appli
agent
rub
skin
aceton
also
enhanc
antigen
passag
extract
epiderm
lipid
discoveri
remark
adjuv
effect
bacteri
adpribosyl
exotoxin
b
bind
subunit
cholera
toxin
structur
similar
heatlabil
toxin
enterotoxigen
e
coli
prompt
much
interest
use
enhanc
cutan
deliveri
group
progress
furthest
clinic
trial
intercel
successor
pioneer
work
begun
us
armi
iomai
see
skin
prepar
system
transcutan
immun
earlier
anoth
group
use
cholera
toxin
adjuv
administ
influenza
vaccin
mice
skin
pretreat
microneedl
safeti
reason
toxin
engin
mutant
select
reduc
toxic
retain
adjuvant
nevertheless
one
use
adjuv
licens
swissmad
intranas
influenza
vaccin
hypothes
caus
temporari
paralysi
seventh
cranial
nerv
bell
palsi
prompt
market
withdraw
chemic
penetr
enhanc
consider
skin
adjuv
alon
conjunct
iontophoresi
ultrasound
electropor
method
includ
oleic
retino
acid
dimethylsulfoxid
dmso
ethanol
limonen
polysorb
other
flagellin
bacteri
surfac
compon
protein
engin
express
influenza
nucleoprotein
epitop
appli
bare
skin
mice
induc
virusspecif
interferongamma
cell
certain
colloid
may
serv
antigen
carrier
deform
lipid
vesicl
transfersom
contain
tetanu
toxoid
appli
anim
skin
yield
compar
immun
respons
alumadjuv
tetanu
toxoid
given
im
rout
novel
method
deliveri
includ
use
short
needl
poke
initi
open
skin
follow
immedi
sc
im
jet
inject
much
lower
pressur
otherwis
would
need
jet
injector
ji
squirt
liquid
high
pressur
deliv
medic
without
needl
target
tissu
tabl
technolog
invent
franc
figur
patent
file
reintroduc
hypospray
patient
selfinject
insulin
see
figur
us
militari
develop
highspe
system
see
figur
imit
other
see
figur
e
f
g
unit
refer
jet
gun
mass
vaccin
program
past
halfcenturi
ji
use
administ
hundr
million
billion
vaccin
dose
mass
campaign
human
smallpox
measl
polio
mening
influenza
yellow
fever
cholera
diseas
swine
influenza
mass
campaign
unit
state
substanti
proport
approxim
million
dose
administ
season
ji
cdc
unpublish
data
ji
also
use
wide
varieti
therapeut
drug
includ
local
pregener
anesthet
antibiot
anticoagul
antivir
corticosteroid
cytotox
immunomodul
insulin
hormon
vitamin
veterinari
model
agricultur
use
widespread
recent
year
devic
use
administ
variou
antigen
human
anim
model
varieti
investig
vaccin
includ
dengu
herp
simplex
type
hivaid
japanes
enceph
malaria
melanoma
increas
concern
needlestick
injuri
possibl
transmiss
bloodborn
pathogen
health
worker
well
expens
needleshield
syring
occup
health
regul
requir
reduc
risk
injuri
boost
interest
ji
develop
countri
anoth
econom
factor
high
cost
proper
dispos
highli
regul
sharp
wast
requir
use
ji
syring
see
disposablesyring
jet
injector
later
latter
may
soil
blood
tissu
fluid
discard
convent
redbag
medic
wast
along
use
bandag
similar
materi
mani
develop
countri
inadvert
intent
reus
nonsteril
needlesyring
seriou
problem
model
indic
signific
cost
save
use
needlefre
ji
compar
needlesyring
especi
indirect
cost
iatrogen
diseas
result
latter
includ
current
best
practic
aim
vaccin
syring
countri
autodis
prevent
reus
goal
far
achiev
common
featur
ji
includ
dose
chamber
suffici
strength
hold
liquid
pressur
move
piston
proxim
end
compress
liquid
tini
orific
commonli
mm
diamet
rang
mm
distal
end
focu
exit
stream
deliveri
patient
piston
major
modern
ji
push
sudden
releas
energi
store
compress
metal
spring
use
compress
ga
co
n
see
tabl
investig
ji
power
expand
pressur
chemic
combust
technolog
similar
found
automot
safeti
air
bag
well
lorentzforc
electromagnet
induct
sourc
energi
compress
spring
usual
suppli
manual
pedal
integr
separ
tool
appli
mechan
advantag
hydraul
pressur
use
electr
power
batteri
wall
main
electr
current
experiment
ji
system
control
electron
microprocessor
propos
cost
practic
routin
immun
remain
unknown
although
devic
vari
peak
pressur
dose
chamber
rang
megapasc
psi
occur
quit
earli
stream
punctur
skin
peak
pressur
drop
one
third
two
third
descend
plateau
phase
rapid
tailoff
end
piston
stroke
veloc
jet
stream
exce
sec
complet
inject
last
second
depend
volum
deliv
orific
crosssect
variabl
ji
classifi
mani
way
energi
storag
sourc
intend
market
human
versu
veterinari
intend
usag
eg
repeat
selfadministr
insulin
patient
versu
vaccin
consecut
patient
dose
chamber
fill
medic
vial
attach
tool
versu
fill
tool
reusabl
entir
devic
singleus
dispos
versu
reusabl
reusabl
fluid
pathway
patientcontact
compon
multius
versu
dispos
last
criterion
result
key
distinct
multiusenozzl
jet
injector
munji
disposablesyring
jet
injector
dsji
call
disposablecartridg
jet
injector
major
implic
immun
safeti
see
safeti
multiusenozzl
jet
injector
disposablesyring
jet
injector
later
vivo
imag
indic
jetinject
medic
tend
spread
along
path
least
resist
gener
conic
distribut
depth
achiev
depend
primarili
power
impart
liquid
variabl
orific
diamet
viscos
dose
taut
thick
skin
fat
layer
angl
inject
sc
compart
reach
mani
dsji
design
selfadministr
patient
insulin
hormon
drug
well
munji
use
dental
anesthesia
eg
fig
munji
develop
mass
vaccin
campaign
power
reach
im
tissuesfor
exampl
pedojet
see
figur
medejet
see
figur
well
sever
newgener
dsji
biojector
vari
orific
differ
cartridg
injector
deliv
either
im
sc
rout
figur
pharmajet
shown
vari
spring
strength
colorcod
injector
im
deliveri
differents
patient
newer
strati
model
sc
deliveri
oper
techniqu
pinch
inject
fat
layer
see
figur
lectrajet
also
vari
spring
strength
model
see
figur
b
marketprimari
use
anesthet
av
antivir
de
dentistri
gh
growth
hormon
ho
hormon
hu
human
medicin
insulin
mu
multipl
st
steroid
un
unspecifi
va
vaccin
veterinari
energi
sourcestorag
ba
batteri
ch
chemic
via
expand
gase
reaction
combust
el
wall
main
electr
ga
compress
ga
cylind
electr
compressor
hy
hydraul
fluid
pressur
footpump
accumul
manual
muscl
pe
pedal
muscl
sp
metal
spring
type
dsji
disposablesyring
jet
injector
munji
multiusenozzl
jet
injector
sudji
singleus
dispos
jet
injector
entir
unit
discard
use
fill
md
multipl
dose
possibl
dose
chamber
refil
requir
mf
manufactur
prefil
tool
dose
chamber
syring
fill
vial
insert
injector
onf
tool
primari
contain
vial
attach
temporarili
injector
fill
dose
chamber
fill
remov
inject
oni
tool
primari
contain
vial
remain
attach
injector
fill
dose
chamber
repeatedli
stay
attach
inject
sd
dose
chamber
prefil
standard
drug
cartridg
primari
contain
target
tissu
id
intraderm
idm
intraderm
multipl
orific
simultan
inject
im
intramuscular
sc
subcutan
howev
may
littl
clinic
relev
may
differ
needl
inject
fatpad
thick
often
underestim
select
needl
length
needl
fulli
insert
russia
unconvent
target
tissueth
lungwa
reach
intrapulmonari
jet
inject
rib
antibiot
bronchodil
steroid
mention
see
cutan
vaccin
earlier
resurg
interest
skin
vaccin
potenti
dosagespar
capabl
minim
invas
jet
injector
classic
id
deliveri
offer
addit
advantag
simplic
tediou
difficult
classic
mantoux
inject
well
abil
use
exist
offtheshelf
vaccin
without
reformul
older
munji
model
pedojet
use
special
nozzl
recess
orific
offset
degre
perpendicular
skin
creat
air
gap
weaken
jet
stream
leav
dose
skin
see
figur
consequ
tst
reaction
size
led
discourag
ji
use
bcg
tst
devic
without
special
id
nozzl
vaccin
attach
spacer
tube
regular
nozzl
creat
gap
orific
skin
weaken
jet
provid
space
bleb
leav
dose
skin
id
techniqu
pursu
investig
local
anesthesia
dna
vaccin
describ
earlier
see
poliomyel
other
involv
polio
erad
pursu
use
dsji
needlefre
dosagespar
id
deliveri
ipv
opv
discontinu
technic
reason
cost
fulldosag
ipv
time
costli
opv
vaccin
studi
id
deliveri
dsji
includ
hivaid
influenza
studi
underway
plan
dengu
human
papillomaviru
rabi
pharmajet
tropi
see
figur
bioject
id
pen
see
figur
two
new
springpow
dsji
design
sole
id
deliveri
ml
volum
former
licens
unit
state
clearanc
latter
expect
larg
bodi
clinic
literatur
show
immunogen
ji
usual
equal
sometim
better
induc
convent
needl
syring
wide
varieti
vaccin
ji
needl
use
deliv
im
sc
inject
compar
term
immedi
pain
result
depend
medic
involv
insulin
nonirrit
drug
nonadjuv
vaccin
usual
report
result
either
reduc
equival
pain
compar
needl
alway
true
doubleblind
needlecontrol
studi
subject
criteria
difficult
implement
thu
rare
except
one
group
appli
earphon
volunt
play
music
loud
enough
mask
mechan
nois
half
receiv
dsji
inject
volunt
insert
arm
screen
block
view
inject
random
needlesyring
group
occur
center
plastic
ring
size
jet
injector
nozzl
group
experienc
skincontact
sensat
prior
inject
nurs
involv
studi
assess
mild
moder
erythema
measur
dsji
vaccine
ns
group
p
mild
moder
indur
occur
dsji
ns
group
respect
p
vaccin
alum
adjuv
irrit
compon
tend
result
higher
frequenc
delay
local
reaction
eg
sore
edema
erythema
jetinject
probabl
small
amount
remain
track
left
skin
superfici
tissu
includ
vaccin
diphtheriatetanuspertussi
whole
cell
hepat
hepat
b
tetanu
tetanusdiphtheria
tetanusdiphtheriapolio
typhoid
case
local
reaction
mild
resolv
within
day
report
compromis
clinic
toler
safeti
chronic
granuloma
report
ji
vaccin
tetanu
toxoid
adsorb
alum
pigment
macul
persist
hepat
b
vaccine
bleed
less
often
ecchymosi
report
occur
jet
inject
site
frequent
needl
inject
rare
jet
stream
may
caus
lacer
health
care
worker
properli
immobil
limb
injector
relat
inject
rare
case
report
advers
event
includ
transient
neuropathi
hematoma
eye
penetr
use
deliv
anesthet
lower
eyelid
surgeri
begin
concern
aros
potenti
iatrogen
transmiss
bloodborn
pathogen
munji
use
nozzl
inject
consecut
patient
without
interven
steril
unpublish
bench
chimpanze
studi
indic
hepat
b
contamin
could
occur
blood
hbsag
remain
nozzl
orific
despit
recommend
alcohol
swab
inject
other
howev
report
neg
result
bench
anim
test
tri
detect
contamin
point
lack
epidemiolog
evid
problem
brink
colleagu
describ
care
anim
model
medejet
transmit
lactat
dehydrogenas
elev
viru
ldv
mice
anim
month
later
fact
supersed
theori
medejet
caus
outbreak
sever
dozen
case
hepat
b
among
patient
california
clinic
subsequ
clinic
field
bench
anim
epidemiolog
studi
ad
evid
munji
could
transmit
pathogen
patient
led
warn
discontinu
use
public
health
author
market
withdraw
pedojet
discontinu
us
militari
use
mid
munji
reengin
dispos
cap
tri
prevent
contamin
blood
tissu
fluid
splash
back
onto
reusabl
nozzl
potenti
infect
next
patient
cap
contain
three
plastic
washer
axial
align
central
hole
mm
diamet
jet
stream
pass
one
direct
along
centimeterwid
gap
orific
skin
howev
inject
salin
volunt
china
carri
hepat
b
viru
subsequ
eject
vialsrepres
next
vaccine
clinic
mass
campaignwer
found
polymeras
chain
reaction
assay
contain
hepat
b
antigen
highspe
microcinematographi
also
reveal
extens
splashback
skin
inject
munji
bodi
evid
support
conclus
design
munji
inher
unsaf
reus
fluid
pathway
unsteril
compon
direct
indirect
contact
consecut
patient
abandon
even
contamin
could
shown
extrem
rare
unlik
policymak
could
convinc
set
level
accept
risk
despit
recommend
munji
use
vaccin
public
health
author
withdraw
us
militari
model
madajet
see
figur
syrijet
continu
use
unit
state
dentistri
podiatri
perhap
specialti
also
despit
chines
venu
definit
studi
document
munji
crosscontamin
chines
food
drug
administr
report
februari
licens
medjet
line
munji
countri
human
applic
russian
regul
april
vaccin
physiatr
dermatolog
mesotherapi
indic
munji
allow
singl
health
worker
vaccin
patient
per
hour
withdraw
devic
pose
challeng
conduct
mass
immun
campaign
diseas
control
program
respons
pandem
bioterror
threat
inde
soviet
biolog
warfar
effort
underway
secret
numer
clinic
trial
publish
highspe
russian
munji
capabl
rapidli
protect
soldier
civilian
potenti
biowarfar
agent
anthrax
botul
plagu
smallpox
tularemia
overcom
concern
munji
withdraw
new
gener
safer
disposablesyring
ji
appear
sinc
earli
see
tabl
figur
steril
syring
cartridg
orific
nozzl
discard
patient
although
mani
use
selfadministr
insulin
hormon
drug
eg
see
figur
e
f
g
target
vaccin
administr
see
figur
b
c
j
newer
system
featur
exampl
autodis
design
prevent
refil
reus
consecut
patient
contempl
developingworld
market
one
uniqu
revolutionari
system
develop
charl
colleagu
institut
pasteur
et
vaccin
predecessor
compani
sanofi
pasteur
manufacturerprefil
imul
syring
see
figur
use
miniimojet
dsji
shown
imul
serv
primari
contain
shipment
vaccin
manufactur
coldchain
storag
well
syring
rubberstopp
bottom
dsji
deliveri
obviat
need
endus
purchas
dispos
although
demonstr
clinic
field
immunogen
safe
diphtheriatetanuspertussi
whole
cell
hepat
influenza
tetanu
typhoid
vaccin
system
eventu
abandon
upon
corpor
merger
pioneer
dsji
vaccin
market
biojector
see
figur
public
us
navi
coast
guard
immun
clinic
unit
state
use
mani
studi
investig
vaccin
see
tabl
anoth
us
compani
pharmajet
enter
market
licensur
eponym
devic
im
sc
inject
subsequ
upgrad
strati
see
figur
variou
model
studi
investig
veterinari
human
applic
influenza
season
ship
sever
hundr
thousand
syring
public
health
agenc
supermarket
drug
chain
market
collaps
octob
surpris
fda
announc
affect
dsji
compani
see
regulatori
matter
later
sinc
meet
develop
world
need
needlefre
vaccin
system
econom
autodis
prevent
reus
suitabl
mass
campaign
routin
immun
us
govern
cdc
us
agenc
intern
develop
nonprofit
organ
path
promot
research
develop
r
util
dsji
technolog
cdc
award
small
busi
innov
research
contract
total
approxim
million
three
compet
compani
one
project
help
develop
highspe
lectrajet
see
figur
uniqu
system
fingersfre
load
unload
cartridg
permit
vaccin
least
person
per
hour
mass
campaign
well
manual
model
share
syring
routin
immun
found
safe
immunogen
influenza
vaccin
licens
unit
state
see
figur
anoth
set
contract
assist
adapt
pharmajet
technolog
id
deliveri
licens
see
figur
third
set
small
busi
innov
research
contract
support
r
zetajet
see
figur
licens
call
vitavax
builtin
handcrank
wind
spring
featur
target
developingcountri
valu
path
also
major
player
field
conduct
r
well
assist
compani
develop
dsji
mention
bill
melinda
gate
foundat
award
path
million
enhanc
close
collabor
industri
determin
valu
appropri
extent
applic
regulatori
pathway
dsji
deliv
vaccin
developingcountri
immun
program
path
initi
dsji
includ
sponsor
coordin
key
polici
analys
id
deliveri
includ
nondsji
mean
econom
model
clinic
trial
multipl
contin
prompt
public
comment
formal
promulg
fda
publish
draft
guidanc
document
pen
jet
relat
injector
intend
use
drug
biolog
product
similar
prior
effort
clarifi
regulatori
landscap
devic
ever
publish
mani
exist
devic
includ
munji
either
grandfath
onto
market
virtu
preced
cutoff
date
medic
devic
regul
clear
sale
basi
substanti
equival
injector
predic
link
back
earlier
devic
draft
document
cover
design
construct
featur
bench
test
aspect
steril
label
issu
importantli
clinic
test
among
mani
docket
submiss
comment
draft
common
observ
propos
guidanc
document
distinguish
suffici
broad
type
devic
coveredinclud
dsji
munji
pen
needl
injectorsand
differ
deserv
distinct
regul
accord
least
burdensom
principl
exampl
level
stringenc
demonstr
safeti
munji
crosscontamin
risk
summar
safeti
multiusenozzl
jet
injector
earlier
appli
also
dsji
anoth
major
critiqu
draft
guidanc
propos
licensur
devic
manufactur
identifi
drugsbiolog
product
current
approv
market
dosag
rate
rout
administr
propos
gener
use
injector
point
path
comprehens
docket
submiss
might
necessarili
requir
conduct
clinic
trial
everi
drug
vaccin
physician
may
decid
administ
would
thu
pose
major
obstacl
innov
develop
gener
use
devic
sold
empti
label
promot
use
particular
drug
reli
clinic
judgment
physician
practic
medicin
accord
evid
scientif
literatur
standard
care
case
needl
syring
would
appli
even
offlabel
use
specif
approv
fda
drug
involv
fda
elegantli
state
june
formal
promulg
guidanc
document
occur
octob
peak
us
influenza
vaccin
season
fda
issu
unusu
surpris
warn
physician
without
usual
advanc
notic
consult
affect
parti
agenc
advis
use
jet
injector
deliv
influenza
vaccin
data
substanti
use
effect
dramat
drugstor
groceri
chain
immedi
cancel
order
expect
sever
million
syring
thousand
accompani
devic
put
risk
surviv
small
compani
involv
within
day
fda
replac
categor
statement
websit
nuanc
one
point
provid
data
manufactur
six
thencurr
usmarket
influenza
vaccin
deliveri
ji
also
cite
limit
data
two
ji
studi
conduct
cdc
involv
demonstr
similar
immun
respons
influenza
vaccin
administ
jet
injector
needl
therefor
fda
cdc
believ
peopl
got
influenza
vaccin
via
jet
injector
need
revaccin
cdc
advisori
committe
immun
practic
mani
year
recogn
jet
inject
effect
method
vaccin
base
substanti
literatur
experi
review
chapter
remain
unknown
whether
standard
care
accept
public
health
medic
practic
restor
market
offlabel
use
whether
vaccin
manufactur
undertak
new
studi
petit
fda
add
jet
inject
product
label
thu
futur
remain
uncertain
small
busi
constitut
global
industri
manufactur
safe
modern
jet
injector
system
vaccin
sinc
earli
histori
immun
respiratori
tract
promis
rout
vaccin
deliveri
howev
respiratori
vaccin
first
becom
part
routin
modern
immun
practic
licensur
intranas
live
attenu
influenza
vaccin
flumist
unit
state
see
chapter
major
potenti
advantag
respiratori
immun
avoid
risk
concern
associ
parenter
inject
gener
provid
stronger
mucos
immun
vaccin
rout
howev
multipl
obstacl
see
challeng
respiratori
deliveri
vaccin
later
restrict
wider
applic
flumist
respiratori
vaccin
gener
use
contrast
respiratori
rout
use
deliv
wide
expand
varieti
pharmaceut
product
import
mucos
immun
prevent
infect
portal
entri
great
major
human
pathogensth
respiratori
gastrointestin
genitourinari
tract
contrast
system
immun
clear
infect
success
invas
limit
replic
destroy
pathogen
ideal
mucos
system
immun
rais
target
pathogen
strong
mucos
immun
may
enhanc
benefit
immun
diseas
exampl
prevent
initi
infect
mucos
immun
reduc
risk
transmiss
other
addit
prevent
clinic
diseas
prevent
infect
mucos
surfac
may
especi
import
diseas
effect
system
immun
difficult
achiev
tuberculosi
aid
everi
mucos
surfac
avail
administ
vaccin
studi
varieti
antigen
anim
model
includ
oral
respiratori
rectal
vagin
ocular
tissu
sever
human
vaccin
alreadi
licens
success
use
deliveri
oral
ingest
includ
polio
cholera
rotaviru
typhoid
adenoviru
see
relev
chapter
book
although
vagin
rectal
vaccin
may
work
would
limit
accept
social
cultur
practic
reason
remaind
chapter
cover
upper
lower
respiratori
tract
focus
devic
technolog
deposit
tissu
optim
present
antigen
respiratori
immun
system
adjuv
enhanc
immun
respons
antigen
present
process
respiratori
tract
like
pathogen
respiratori
vaccin
antigen
enter
airborn
particl
nare
mouth
airway
design
foil
entri
passag
particl
inspir
nose
first
filter
nasal
hair
must
travers
extern
nasal
valv
slitlik
passag
limit
airflow
nare
intern
nasal
airway
djupesland
colleagu
show
larg
highspe
droplet
averag
tradit
nasal
spray
reach
beyond
extern
nasal
valv
nasal
filtrat
system
may
bypass
oral
deliveri
via
mask
mouthpiec
howev
larg
highspe
particl
stop
mouth
small
particl
inhal
via
nose
mouth
share
common
pathway
oropharynx
larynx
trachea
bifurc
trachea
right
left
bronchi
start
seri
bifurc
provid
surfac
trap
airborn
particl
small
light
slowmov
particl
succeed
navig
tortuou
pulmonari
passag
deposit
lower
airway
smallest
particl
may
reach
alveoli
rapidli
absorb
system
circul
complex
branch
lung
passag
also
result
astonish
alveolar
surfac
area
exceed
squar
meter
human
adult
male
compar
averag
squar
centimet
nasal
airway
lower
airway
human
typic
organ
lymphoid
tissu
abund
intraepitheli
dendrit
cell
alveolar
macrophag
process
antigen
intern
nasal
airway
particl
deposit
nasal
mucosa
cover
turbin
join
flow
mucu
swept
ciliat
epithelia
toward
pharynx
swallow
immun
surveil
antigen
flow
mucu
begin
taken
epitheli
cell
intraepitheli
dendrit
cell
surfac
macrophag
microfold
cell
cell
special
epitheli
cell
take
macromolecul
virus
bacteria
endocytosi
present
lymphocyt
dendrit
cell
congreg
invagin
pocket
cell
pocket
commun
extracellular
space
see
figur
predomin
organ
lymphoid
tissu
human
respiratori
tract
locat
pharynx
adenoid
tonsil
collect
known
waldey
ring
surround
nasal
oral
passag
epithelium
overli
tissu
rich
cell
increas
deposit
vaccin
antigen
posterior
nasal
passag
nasopharynx
near
waldey
ring
may
desir
maxim
immun
respons
breath
actuat
nasal
spray
nasal
inhal
smaller
aerosol
particl
two
method
increas
nasopharyng
deposit
see
figur
b
antigenpres
cell
respiratori
tract
drain
region
lymph
node
b
cell
preferenti
switch
iga
plasmablast
plasmablast
home
back
airway
epithelium
provid
antigenspecif
iga
protect
cell
also
play
major
role
mucos
immunolog
memori
respons
lymphocyt
expos
antigen
respiratori
tract
migrat
provid
protect
remot
mucos
site
vagina
integr
network
immun
cell
tissu
known
common
mucos
immun
system
respiratori
tract
expos
myriad
nonpathogen
macromolecul
mechan
downregul
immun
respons
antigen
exposur
immunolog
toler
must
consid
develop
respiratori
immun
strategi
first
challeng
respiratori
immun
determin
appropri
target
tissu
respiratori
drug
tradit
target
two
area
exampl
nasal
passag
desir
site
action
decongest
lower
airway
target
asthma
medic
optim
target
tissu
yet
understood
potenti
respiratori
vaccin
vari
differ
antigen
pharyng
tonsil
like
candid
target
key
role
immunolog
prime
vaccin
may
requir
deposit
lower
airway
uptak
alveolar
macrophag
dendrit
cell
scientif
method
evalu
compar
differ
target
tissu
yet
well
develop
second
challeng
difficulti
select
anim
model
extrapol
result
human
respiratori
vaccin
deliveri
interspeci
differ
respiratori
immunolog
tissu
organ
limit
interpret
anim
targettissu
research
result
human
moreov
size
anatomi
respiratori
tract
common
research
anim
differ
greatli
human
exampl
small
anim
rodent
nose
drop
may
deposit
entir
respiratori
tract
would
case
human
balmelli
colleagu
estim
vaccin
given
mice
drop
deposit
lung
mani
virus
bacteria
infect
human
grow
well
anim
model
exampl
speciesspecif
differ
distribut
sialic
acid
receptor
cell
surfac
crucial
factor
tissu
host
specif
influenza
virus
limit
number
anim
model
suitabl
influenza
research
speciesspecif
differ
make
difficult
use
anim
studi
attenu
live
vaccin
vaccin
vector
well
challeng
anim
assess
protect
imped
develop
safe
effect
respiratori
vaccin
human
third
challeng
respiratori
immun
dosag
accuraci
mass
volum
antigen
deliv
depend
mani
factor
includ
variabl
perform
respiratori
deliveri
devic
behavior
techniqu
person
administ
vaccin
differ
anatomi
physiolog
vaccin
anim
vaccine
human
fortun
mani
vaccin
wide
margin
dosag
necessari
induc
protect
dosag
risk
advers
event
increas
licensur
unit
state
europ
first
inhal
insulin
exubera
drug
dosag
accuraci
consist
critic
suggest
challeng
overcom
respiratori
vaccin
howev
commerci
failur
exubera
pose
cautionari
exampl
develop
potenti
aerosol
vaccin
product
withdrawn
market
manufactur
lack
sale
nearli
billion
invest
develop
licensur
major
reason
cite
market
failur
patient
physician
concern
longterm
safeti
complex
size
deliveri
devic
increas
cost
compar
inject
avail
newer
inject
devic
insulin
pen
fourth
major
challeng
lack
accept
correl
protect
mucos
immun
contrast
mani
diseas
laboratori
assay
measur
wellestablish
criteria
system
immunitysuch
antibodi
titer
certain
cutoffsthat
serv
mani
year
predict
protect
diseas
absenc
accept
serolog
cellular
correl
protect
induc
mucos
vaccin
clinic
trial
must
use
specif
diseaseprevent
endpoint
make
studi
much
larger
expens
sever
immun
safeti
issu
repres
challeng
respiratori
vaccin
one
risk
vaccin
antigen
live
inactiv
adjuv
excipi
might
affect
nearbi
cranial
nerv
might
travel
along
olfactori
nerv
cribriform
plate
brain
result
advers
central
nervou
system
effect
vaccin
target
lower
airway
may
induc
exacerb
bronchospasm
pulmonari
inflamm
life
threaten
anoth
risk
crosscontamin
respiratori
pathogen
one
patient
may
contamin
respiratori
immun
devic
spread
subsequ
patient
also
vaccin
aerosol
may
spread
beyond
intend
vaccine
affect
person
vicin
final
live
viru
bacteri
vaccin
might
pose
increas
risk
immunocompromis
person
deliv
via
respiratori
tract
remain
challeng
relat
deliveri
devic
although
mani
alreadi
exist
deliv
drug
respiratori
tract
design
vaccin
respiratori
drug
devic
deliv
repetit
dose
singl
patient
contrast
expect
usag
vaccin
devic
deliv
singl
dose
multipl
patient
rais
crosscontamin
issu
although
singleus
dispos
devic
devic
compon
could
solv
problem
must
inexpens
cost
effect
aerosoldrug
deliveri
devic
requir
patient
educ
obtain
need
cooper
adequ
dose
deliveri
may
difficult
brief
time
typic
involv
vaccin
young
children
receiv
mani
vaccin
respiratori
deliveri
method
effect
although
current
respiratori
drug
deliveri
devic
typic
target
anterior
nasal
passag
lower
airway
respiratori
vaccin
may
work
best
quit
differ
target
pharyng
tonsil
theori
ideal
nasal
deliveri
devic
would
prolong
effect
antigen
present
deposit
larg
surfac
area
intern
nasal
airway
allow
mucu
flow
move
vaccin
gradual
across
tonsil
new
deliveri
technolog
achiev
respiratori
immun
requir
rout
becom
practic
accept
young
field
publish
research
limit
relev
devic
anim
human
report
anim
studi
deliveri
devic
mention
laboratori
pipett
use
intranas
instil
would
unsuit
human
respiratori
devic
design
human
test
difficult
imposs
anim
model
last
perhap
signific
challeng
implement
respiratori
vaccin
novel
vaccin
deliveri
system
routin
immun
practic
regulatori
requir
need
ensur
novel
system
safe
effect
studi
clinic
trial
need
extrem
expens
vaccin
manufactur
typic
reluct
assum
cost
risk
relicens
exist
product
alreadi
deliv
profit
unless
potenti
benefit
market
advantag
would
signific
best
opportun
bring
altern
deliveri
routin
practic
may
use
new
deliveri
system
start
new
vaccin
earli
develop
licensur
process
vaccin
deliv
respiratori
tract
directli
either
liquid
drypowd
aerosol
current
licens
vaccin
inject
oral
nasal
deliveri
either
store
administ
liquid
store
dri
form
reconstitut
liquid
prior
administr
deliveri
liquid
aerosol
thu
closer
usual
practic
also
gener
easier
perform
anim
studi
gener
aerosol
exist
liquid
formul
dri
aerosol
requir
chang
formul
manufactur
vaccin
achiev
sustain
vaccin
potenc
powder
dispers
challeng
met
dri
aerosol
sever
advantag
liquid
aerosol
see
drypowd
formul
respiratori
deliveri
later
devic
current
licens
use
unit
state
respiratori
vaccin
deliveri
accuspray
use
flumist
live
attenu
influenza
vaccin
laiv
devic
steril
singlepatientus
dispos
prefil
glass
syring
fix
nonremov
plastic
nozzl
figur
total
dose
ml
ml
spray
consecut
nostril
attach
plunger
tell
user
switch
nostril
flumist
vaccin
deliv
accuspray
highli
effect
popul
see
chapter
key
advantag
accuspray
deliveri
simplic
use
low
cost
dispos
outsid
sharp
wast
difficulti
refil
reus
larg
particl
size
gener
sprayer
minim
deposit
lower
airway
reduc
risk
advers
pulmonari
event
limit
system
particl
size
emit
depend
speed
vaccin
depress
plunger
median
diamet
particl
rang
greater
plunger
speed
mmsec
less
speed
mmsec
greater
although
wide
variabl
might
theori
affect
effici
vaccin
deposit
laiv
accuspray
produc
high
rate
protect
immun
current
dosag
fluoresc
focu
unit
ffu
three
strain
includ
vaccin
assess
potenti
administr
measl
vaccin
simon
cowork
conduct
clinic
trial
live
attenu
moraten
berna
measl
vaccin
use
nebul
util
batterypow
piezoelectr
energi
drive
aerosol
dispos
drug
cartridg
via
microperfor
mesh
plate
dispos
patient
interfac
f
nasal
prong
patient
nostril
oral
prong
mask
shown
droplet
diamet
tailor
upper
lower
airway
deliveri
respect
figur
courtesi
lui
valdespino
instituto
nacion
de
salud
accuspray
administr
produc
protect
serum
antibodi
titer
nonimmun
individu
compar
protect
titer
volunt
receiv
vaccin
sc
rout
notabl
vaccin
result
increas
product
measlesvirusspecif
secretori
iga
siga
oral
fluid
nasal
wash
among
previous
nonimmun
individu
without
evid
system
immun
respons
anoth
respiratori
immun
devic
use
human
jet
nebul
system
known
classic
mexican
devic
cmd
see
figur
b
slight
modif
nebul
system
use
deliv
live
attenu
measl
vaccin
multipl
clinic
trial
mexico
south
africa
also
vaccin
million
mexican
children
measl
mass
campaign
system
consist
generalus
nonmedicalgrad
compressor
deliv
air
jet
nebul
ipi
hold
vaccin
crush
ice
maintain
potenc
vaccin
session
vaccin
aerosol
deliv
reusabl
plastic
tube
singleus
dispos
paper
cone
modifi
drink
cup
held
close
patient
face
second
typic
aerosol
dose
volum
roughli
ml
mass
median
aerosol
diamet
droplet
recent
studi
bennett
colleagu
dose
child
deliv
cmd
singleus
dispos
plastic
bag
avoid
risk
crosscontamin
tube
reservoir
separ
tube
child
inhal
content
via
oneway
valv
mask
preschoolag
children
vaccin
aerosol
reservoir
develop
higher
antibodi
gmt
subject
vaccin
sc
rout
studi
assess
distribut
viabl
vaccin
viru
across
rang
droplet
size
emit
cmd
coat
cowork
estim
infect
viral
particl
contain
droplet
diamet
less
droplet
greater
although
cmd
demonstr
level
safeti
immunogen
heavi
cumbersom
noisi
requir
outlet
main
electr
crush
ice
thu
practic
routin
vaccin
encourag
result
earli
measl
aerosol
vaccin
trial
see
classic
mexican
devic
nebul
earlier
live
virus
later
partnership
cdc
american
red
cross
initi
measl
aerosol
project
map
goal
licensur
least
one
live
attenu
measl
vaccin
associ
aerosol
deliveri
system
develop
world
project
document
immunogen
safeti
ie
lack
local
system
toxic
anim
studi
three
exist
therapeut
nebul
use
phase
clinic
trial
aeroeclips
compair
aeroneb
select
criteria
critic
perform
data
usabl
field
condit
vaccin
potenc
nebul
exist
licensur
use
measl
vaccin
deliveri
three
devic
deliv
subject
india
report
safe
well
toler
immunogen
modifi
version
aeroneb
devic
select
use
phase
pivot
trial
initi
map
studi
random
openlabel
activecontrol
noninferior
trial
measl
vaccin
unvaccin
healthi
infant
month
age
novemb
studi
result
releas
publish
optimist
breathactu
nasalspray
devic
deliv
liquid
drypowd
aerosol
oral
exhal
rais
soft
palat
close
connect
nose
throat
pulmonari
deposit
avoid
deliveri
posterior
nasal
segment
increas
see
figur
b
human
studi
inactiv
influenza
vaccin
selfadminist
use
optimist
result
signific
increas
virusspecif
iga
nasal
secret
well
protect
level
virusspecif
serum
antibodi
two
dose
subject
combitip
plu
pipett
dispens
use
deliv
drypowd
neisseria
meningitidi
vaccin
human
subject
vaccin
rout
serum
bactericid
antibodi
titer
compar
vaccin
convent
inject
vaccine
protect
titer
second
dose
one
third
vaccine
report
mild
side
effect
compar
two
third
inject
vaccine
report
mild
inject
pain
anoth
drypowd
inhal
singleus
dispos
twincer
figur
dispers
inulinbas
drypowd
subunit
influenza
vaccin
aerodynam
particl
size
distribut
suitabl
pulmonari
administr
two
uniqu
drypowd
deliveri
devic
puffhal
see
figur
b
becton
dickinson
bd
solov
see
figur
develop
test
part
initi
develop
measl
vaccin
dri
powder
mvdp
project
led
aktivdri
llc
see
drypowd
formul
respiratori
deliveri
later
devic
dispers
mvdp
inexpens
singleus
dispos
reservoir
patient
inhal
elimin
risk
crosscontamin
success
demonstr
cottonrat
model
mvdp
evalu
rhesu
macaqu
use
puffhal
bd
solov
via
mask
via
direct
rout
devic
respiratori
deliveri
induc
robust
signific
measlesspecif
humor
tcell
respons
advers
effect
challeng
year
later
mvdpvaccin
macaqu
protect
infect
wildtyp
measl
viru
studi
bd
solov
effect
direct
nasal
deliveri
influenza
vaccin
rat
anthrax
vaccin
rabbit
cdc
develop
aerovax
nebul
see
figur
f
collabor
crear
inc
util
dispos
patient
interfac
nasal
prong
oral
prong
mask
dispos
drug
cartridg
prevent
crosscontamin
dispos
drug
cartridg
manufactur
gener
custom
particl
size
distribut
eg
droplet
upperairway
deliveri
droplet
less
reach
lower
airway
deliveri
live
attenu
measl
vaccin
via
nasal
prong
shown
safe
immunogen
macaqu
aerosol
deliveri
aerovax
devic
influenza
viru
induc
robust
immun
respons
mice
protect
homolog
heterolog
influenza
challeng
nasal
aerosol
deliveri
laiv
ferret
elicit
high
level
serum
neutral
antibodi
protect
homolog
viru
challeng
convent
median
tissu
cultur
infect
dose
tcid
significantli
reduc
tcid
dosag
provid
signific
level
subtypespecif
crossprotect
aerovectrx
inc
acquir
right
manufactur
distribut
technolog
investig
devic
nasal
deliveri
drypowd
vaccin
nasopharyng
tissu
develop
cdc
crear
inc
see
figur
oper
patient
exhal
mouth
blow
powder
nose
simultan
gener
air
flow
limit
entri
lower
respiratori
tract
deposit
pattern
target
nasal
tissu
document
threedimension
plastic
model
develop
cfdrc
inc
vivo
computer
tomographi
child
head
figur
see
figur
devic
deliv
vaccin
appropri
region
respiratori
tract
suffici
quantiti
antigen
adjuv
need
must
penetr
mucos
alveolar
barrier
gain
access
appropri
cell
activ
immun
system
vehicl
vector
use
purpos
includ
live
attenu
virus
includ
act
vector
exogen
antigen
live
attenu
bacteria
includ
vector
commens
bacteri
vector
virosom
viruslik
particl
vlp
liposom
lipopeptid
immun
stimul
complex
iscom
microparticl
nanoparticl
virus
prototyp
antigendeliveri
vehicl
enter
command
cell
replic
thu
multipli
avail
antigen
encod
also
virus
induc
natur
adjuv
effect
activ
chemokin
cytokin
wide
studi
respiratori
deliveri
vehicl
live
attenu
strain
pathogen
virus
major
risk
possibl
revers
virul
potenti
neurotox
via
olfactori
rout
potenti
pathogen
effect
immunocompromis
person
coldadapt
laiv
flumist
vaccin
current
licens
unit
state
deliveri
rout
develop
test
licensur
review
detail
chapter
laiv
deliv
rout
demonstr
sever
potenti
benefit
method
produc
mucos
system
immun
provid
higher
protect
efficaci
inject
inactiv
vaccin
young
children
provid
heterotyp
immun
influenza
strain
antigen
drift
vaccin
strain
may
reduc
risk
influenza
transmiss
reduc
respiratori
shed
among
immun
children
challeng
later
vaccin
viru
final
modest
coverag
laiv
among
school
children
reduc
influenzarel
ill
rate
unvaccin
adult
commun
influenza
measl
nextmoststudi
diseas
vaccin
deliveri
via
respiratori
tract
pioneer
albert
sabin
later
year
career
evid
base
prompt
measl
aerosol
project
describ
earlier
review
metaanalys
multipl
clinic
studi
reveal
three
basic
immunerespons
pattern
measl
vaccin
first
drop
spray
deliv
conjunctiva
oral
nasal
mucosa
produc
inconsist
immun
respons
second
deliveri
smallparticl
liquid
aerosol
via
pulmonari
inhal
children
month
age
older
typic
produc
immun
respons
high
proport
subject
respons
aerosol
vaccine
usual
equival
greater
respons
inject
vaccin
exampl
dilraj
colleagu
found
schoolchildren
receiv
aerosol
measl
vaccin
antibodi
titer
greater
iuml
year
vaccin
respect
compar
among
inject
vaccine
third
pattern
note
gener
lower
immun
respons
aerosol
rout
compar
parenter
inject
among
children
younger
month
exampl
wongchew
cowork
found
vaccin
month
old
infant
inject
induc
immun
aerosol
rout
respect
one
hypothesi
low
respiratori
minut
volum
young
infant
result
small
dose
aerosol
vaccin
period
time
followup
studi
wongchew
colleagu
demonstr
increas
exposur
time
aerosol
measl
vaccin
elicit
immun
respons
compar
seen
equival
dose
administ
sc
rout
month
old
infant
regard
vaccin
safeti
review
metaanalys
note
sever
advers
event
report
aerosol
measl
vaccin
studi
rate
minor
advers
event
report
typic
less
vaccin
inject
deliveri
live
attenu
rubella
vaccin
investig
mani
clinic
trial
ganguli
cowork
demonstr
drop
spray
vaccin
viru
produc
mucos
iga
antibodi
equival
serum
igg
antibodi
better
protect
reinfect
compar
sc
vaccin
subject
receiv
challeng
howev
higher
rate
mild
advers
event
usual
rhiniti
sore
throat
recent
studi
bennett
colleagu
found
aerosol
vaccin
preschool
children
combin
measlesmumpsrubella
vaccin
produc
antibodi
respons
rubella
mump
equival
produc
inject
cowork
found
aerosol
measlesrubella
combin
vaccin
schoolag
children
previous
vaccin
rubella
produc
high
level
rubella
immun
equival
seen
sc
inject
fewer
advers
event
report
aerosol
group
diaz
ortega
colleagu
found
measlesmumpsrubella
vaccin
aerosol
colleg
student
produc
immun
respons
similar
produc
inject
seroposit
retain
vaccine
year
vaccin
recombin
virus
act
vector
incorpor
gene
express
heterolog
antigen
advantag
similar
convent
attenu
live
viru
vaccin
deliv
genet
code
antigen
cell
replic
activ
immun
system
virus
use
vaccin
vector
ideal
low
pathogen
potenti
even
immunocompromis
peopl
well
capac
incorpor
necessari
foreign
gene
desir
antigen
promot
adjuv
virus
natur
infect
grow
respiratori
tissu
especi
well
suit
vector
respiratori
immun
studi
anim
model
includ
adenovirus
alpha
virus
poxvirus
baculoviru
vesicular
stomat
viru
adenoassoci
viru
adenoviru
vector
deliv
sever
anim
model
produc
immun
respons
mani
diseas
exampl
defectivecomplex
adenoviru
contain
ebola
viru
gene
protect
nonhuman
primat
aerosol
challeng
two
ebola
speci
vaccinia
strain
modifi
vaccinia
ankara
mva
also
use
effect
vector
respiratori
immun
mva
vector
express
antigen
induc
rout
antigenspecif
mucos
cell
genit
tissu
drain
lymph
node
mice
along
serum
vagin
antibodi
one
caveat
use
vector
vaccin
preexist
immun
popul
vector
viru
either
natur
exposur
previou
use
anoth
vaccin
may
reduc
effect
howev
song
colleagu
report
seri
studi
adenovirusvector
vaccin
deliv
fine
aerosol
lung
produc
strong
immunogen
even
anim
preexist
antiadenovir
immun
suggest
pulmonari
deliveri
may
overcom
limit
viral
vector
vaccin
anim
model
respiratori
immun
use
studi
attenu
respiratori
pathogen
vaccin
mycobacterium
bovi
bcg
attenu
bordetella
pertussi
well
nonrespiratori
pathogen
salmonella
shigella
act
recombin
vector
mous
studi
also
demonstr
improv
immun
respons
convent
bcg
vaccin
deliv
rout
aerosol
inhal
compar
inject
studi
includ
challeng
found
respiratori
rout
provid
better
protect
inject
attenu
tuberculosi
also
immunogen
respiratori
rout
vector
bacteria
advantag
virus
higher
capac
insert
heterolog
gene
express
antigen
adjuv
plasmid
dna
vaccin
see
next
section
dna
vaccin
involv
deliveri
eponym
plasmid
directli
host
cell
express
desir
antigen
deliveri
nake
dna
respiratori
tract
vaccin
studi
anim
model
mani
diseas
exampl
kuklin
associ
found
nasal
deliveri
herp
simplex
dna
vaccin
gener
higher
level
vagin
iga
im
rout
although
im
vaccin
produc
stronger
serum
antibodi
better
protect
challeng
live
attenu
bacteria
especi
salmonella
shigella
vector
produc
dna
vaccin
exampl
cotton
rat
vaccin
attenu
salmonella
vaccin
express
dna
encod
measl
antigen
result
signific
reduct
measl
viru
titer
lung
tissu
challeng
virosom
liposom
microparticl
carrier
vaccin
antigensdiscuss
nexthav
also
deliv
dna
respiratori
rout
synthet
construct
includ
liposom
viruslikeparticl
vlp
virosom
immunostimul
complex
iscom
microparticl
nanoparticl
nonrepl
deliveri
system
mimic
live
virus
appear
immun
system
enhanc
antigen
deliveri
may
also
carri
adjuv
terminolog
mutual
exclus
term
use
synonym
particl
size
virus
allow
similar
uptak
antigenpres
cell
mani
includ
lipid
compon
increas
cell
membran
permeabl
may
contain
unrel
viral
bacteri
protein
activ
immun
system
liposom
vesicl
compos
phospholipid
bilay
membran
antigen
packag
aqueou
core
insid
lipid
bilay
outsid
membran
liposom
vaccin
deliv
mice
rout
result
strong
igg
iga
respons
serum
vagin
wash
vlp
aggreg
viral
protein
may
includ
lipid
compon
virosom
lipid
bilay
membran
embed
viral
protein
resembl
virus
except
lack
genet
materi
need
replic
cusi
cowork
vaccin
mice
rout
reconstitut
influenza
virosom
assembl
plasmid
express
carcinoembryon
antigen
cea
gene
intranas
vaccin
mice
develop
ceaspecif
antibodi
protect
challeng
ceaexpress
mastocytoma
cell
howev
cea
virosom
vaccin
coadminist
rout
reconstitut
influenza
virosom
plasmid
express
gene
adjuv
level
antibodi
increas
mice
protect
tumorcel
challeng
iscom
cagelik
structur
roughli
nm
size
compos
subunit
saponin
quil
cholesterol
sever
antigen
administ
iscombas
vaccin
produc
strong
system
mucos
immun
respons
exampl
administr
iscom
tuberculosi
recombin
protein
strongli
boost
prior
bcg
immun
reduc
bacteri
burden
lung
compar
nonboost
mice
respiratori
deliveri
also
enhanc
packag
antigen
adjuv
microparticl
nanoparticl
compos
polym
biodegrad
materi
polylactid
pla
polylactid
coglycolid
plga
biopolym
chitin
chitosan
microparticl
design
slowli
releas
antigen
increas
durat
antigen
present
carcaboso
colleagu
report
mice
immun
rout
synthet
malaria
vaccin
encapsul
microparticl
plga
significantli
higher
antigenspecif
serum
igg
titer
control
mice
given
vaccin
sc
rout
alum
adjuv
pulmonari
immun
chitosan
microparticl
contain
diphtheria
toxoid
result
neutral
antibodi
titer
compar
significantli
higher
achiev
sc
administr
alumadsorb
diphtheria
toxoid
vaccin
base
deliveri
system
could
potenti
formul
powder
direct
deliveri
dri
state
techniqu
grow
interest
exampl
pubm
search
octob
use
term
vaccin
powder
yield
articl
publish
sinc
relat
respiratori
deliveri
powder
vaccin
compar
two
prior
year
number
obstacl
must
overcom
produc
success
respir
vaccin
dri
particl
size
suitabl
deliveri
respiratori
tract
first
formul
powder
requir
signific
extens
chang
manufactur
method
even
use
current
lyophil
vaccin
second
mani
potenti
dri
formul
ingredi
extrem
hygroscop
gum
expos
humid
engin
need
maintain
structur
dispers
deliveri
dri
state
third
powder
deposit
respiratori
tract
must
suffici
hygroscop
dissolv
releas
vaccin
uptak
anoth
challeng
drypowd
deliveri
devic
requir
activ
inhal
patient
thu
may
impract
small
children
two
potenti
solut
age
group
howev
direct
nasal
deliveri
well
dispens
powder
reservoir
see
eg
figur
b
child
breath
normal
hand
sever
signific
potenti
advantag
drypowd
vaccin
dose
fill
inexpens
singleus
present
deliv
without
onsit
aqueou
reconstitut
thu
avoid
occasion
human
error
result
use
wrong
contamin
diluent
cost
ship
store
diluent
would
avoid
secondari
packag
seal
dose
contain
imperm
overwrap
metal
foil
could
maintain
low
humid
may
prolong
potenc
increas
shelf
life
recent
progress
improv
thermost
liquid
vaccin
even
dri
one
point
futur
mani
vaccin
may
requir
cold
chain
measl
vaccin
pathfind
applic
respiratori
deliveri
dri
powder
earli
formul
fine
mill
retain
adequ
potenc
immun
respons
poor
deliv
respiratori
tract
macaqu
activ
develop
aktivdri
work
partner
includ
serum
institut
india
sii
cdc
univers
colorado
mvdp
project
award
million
grand
challeng
global
health
grant
bill
melinda
gate
foundat
refin
formul
establish
drypowd
measl
vaccin
product
capac
sii
complet
anim
phase
clinic
test
aktivdri
use
novel
spraydri
system
manufactur
inhal
mvdp
start
bulk
liquid
siiprovid
live
attenu
antigen
contain
myoinositol
stabil
viru
plaqu
assay
demonstr
potenc
loss
dri
process
compar
loss
seen
lyophil
report
earlier
end
product
demonstr
immunogen
cotton
rat
rhesu
macaqu
licensuregrad
toxicolog
studi
found
testarticlerel
effect
delay
onset
toxic
inhal
spraguedawley
rat
second
toxicolog
studi
administr
mask
use
either
bd
solov
puffhal
measlesseroneg
rhesu
macaqu
produc
effect
mortal
clinic
observ
respiratori
function
clinic
patholog
histopatholog
sii
manufactur
mvdp
clinic
trial
applic
approv
drug
control
gener
india
conduct
phase
safeti
trial
adult
adolesc
infant
use
puffhal
bd
solov
devic
trial
began
may
separ
project
report
ohtak
cowork
found
drypowd
measl
vaccin
made
mild
spraydri
uniqu
stabil
stabl
week
c
drypowd
vaccin
influenza
formul
test
sever
group
whole
inactiv
viru
product
deliv
rout
rat
elicit
high
titer
nasal
antiinfluenza
iga
well
serum
antibodi
titer
equival
obtain
inject
vaccin
loss
potenc
found
store
c
rel
humid
week
c
rel
humid
week
anoth
formul
produc
sprayfreez
dri
subunit
viral
antigen
inulin
stabil
induc
upon
pulmonari
deliveri
humor
igg
cellmedi
interferon
gamma
mucos
iga
igg
immun
respons
balbc
mice
pulmonari
rout
sprayfreez
dri
whole
inactiv
viru
vaccin
stabil
inulin
provid
protect
similar
provid
im
inject
mice
expos
lethal
dose
live
viru
humandiseas
target
drypowd
deliveri
studi
includ
tuberculosi
hepat
b
noroviru
gastroenter
anthrax
plagu
spraydri
formul
adenovirusvector
tuberculosi
antigen
mannitolbas
stabil
shown
characterist
suitabl
pulmonari
deliveri
term
thermodynam
water
absorpt
particl
size
distribut
morpholog
viru
surviv
nanoparticleaggreg
formul
contain
recombin
hepat
b
surfac
antigen
administ
lung
guinea
pig
produc
high
igg
iga
titer
nasal
vaccin
norwalkviru
vlp
inert
situ
gell
polysaccharid
induc
system
mucos
antibodi
titer
equal
greater
achiev
vlp
plu
adjuv
liquid
formul
deliv
rout
drypowd
vaccin
bioweapon
threat
studi
exampl
anthrax
vaccin
rout
provid
complet
protect
inhal
challeng
roughli
time
median
lethal
dose
ld
rabbit
provid
better
stabil
liquid
formul
stabl
powder
vaccin
yersinia
pesti
administ
rout
mice
requir
extra
dose
vaccin
achiev
protect
similar
im
deliveri
plagu
lethal
challeng
nonrepl
antigen
deliv
via
respiratori
tract
typic
poorli
immunogen
may
requir
adjuv
stimul
appropri
immun
respons
adjuv
studi
purpos
includ
bacteri
toxin
deriv
bacteri
compon
bacteri
dna
motif
cytokin
chemokin
plant
deriv
nanoemuls
toxin
cholera
toxin
ct
e
coli
heatlabil
toxin
potent
adjuv
nativ
form
may
toxic
use
human
see
bacteri
exotoxin
earlier
lt
adjuv
commerci
swiss
influenza
vaccin
deliveri
suspect
reason
manyfold
increas
risk
bell
palsi
vaccin
lead
market
withdraw
vaccin
although
pathogenesi
vaccin
effect
seventh
cranial
nerv
uncertain
branch
nerv
run
near
nose
advers
neurolog
effect
ct
lt
hypothes
base
accumul
olfactori
bulb
balbc
mice
nasal
administr
sometim
concurr
inflamm
result
recent
adjuv
research
focus
subunit
detoxifi
version
variant
ct
lt
sever
accumul
olfactori
bulb
balbc
mice
bacteri
product
induc
potent
activ
innat
immun
system
includ
lipopolysaccharid
deriv
monophosphoryl
lipid
well
outer
membran
protein
flagellin
lipopeptid
filament
hemagglutinin
proteosom
last
outer
membran
protein
meningococci
selfassembl
hydrophob
proteinac
nanoparticl
intranas
deliv
proteosomebas
inactiv
influenza
vaccin
produc
serum
mucos
antibodi
human
subject
n
meningitidi
b
proteoliposomederiv
cochleat
demonstr
potent
mucos
adjuv
three
dose
tetanu
toxoid
vaccin
adjuv
administ
rout
mice
promot
igg
serum
titer
iga
titer
saliva
vagin
wash
significantli
higher
tetanu
toxoid
alon
oligodeoxynucleotid
cytosin
guanin
phosphodiest
backbon
cpg
odn
mimic
motif
found
bacteri
dna
potent
adjuv
innat
immun
system
recogn
pathogenassoci
molecular
pattern
abe
colleagu
found
nontyp
h
influenza
nthi
vaccin
deliv
rout
cpg
odn
produc
mucos
iga
serum
igg
respons
similar
produc
vaccin
deliv
ct
enhanc
clearanc
nthi
nasopharynx
challeng
shown
equal
group
inclus
cpg
odn
four
hiv
peptid
antigen
microparticl
deliv
rout
mice
significantli
enhanc
peptidespecif
igg
iga
peak
titer
prolong
durat
antibodi
increas
siga
respons
mucos
wash
howev
anoth
studi
daili
inject
highdosag
g
cpg
result
lymphoid
follicl
destruct
immunosuppress
liver
necrosi
day
therefor
potenti
advers
effect
cpg
odn
studi
mani
adjuv
induc
activ
cytokin
chemokin
investig
look
cellular
signal
molecul
adjuv
might
reduc
adjuv
toxic
cytokin
ad
directli
vaccin
encod
express
live
vector
dna
vaccin
bracci
colleagu
found
mice
singl
dose
inactiv
influenza
vaccin
provid
full
protect
viru
challeng
cytokin
interferon
type
includ
adjuv
without
dosag
partial
protect
mice
administr
pneumococc
surfac
protein
tetanu
toxoid
combin
cytokin
induc
protect
immun
equival
induc
parenter
deliveri
chitin
natur
polysaccharid
found
crustacean
partial
deacetyl
yield
chitosan
wide
use
food
product
excipi
drug
nutrit
supplement
chitin
chitosan
mucoadhes
properti
stimul
innat
immun
system
human
addit
chitosan
detoxifi
diphtheria
toxin
base
significantli
increas
toxinneutr
antibodi
level
upon
deliveri
saponin
quillaja
saponaria
tree
potent
adjuv
high
toxic
quil
iscoprep
q
saponaria
deriv
less
toxic
adjuv
dna
vaccin
studi
mice
consist
increas
antigenspecif
serum
igg
mucos
iga
compar
vaccin
without
adjuv
quil
iscoprep
commonli
use
compon
immunostimul
complex
combin
adjuv
respiratori
vaccin
may
synergist
enhanc
immun
protect
exampl
deliveri
mice
influenza
recombin
hemagglutinin
rha
antigen
along
combin
proteosom
lipopolysaccharid
adjuv
enhanc
serum
igg
mucos
iga
antibodi
compar
vaccin
alon
also
deliveri
influenza
vaccin
combin
adjuv
vector
superior
vaccin
formul
use
iscom
adjuv
alon
nanoemuls
anoth
class
adjuv
studi
respiratori
vaccin
soybean
oilinwat
nanoemuls
mix
either
uslicens
fluzon
fluvirin
inactiv
influenza
vaccin
usual
inject
im
rout
deliv
rout
ferret
result
seroconvers
rate
three
viral
strain
present
vaccin
also
protect
homolog
viral
challeng
signific
crossimmun
five
influenza
viru
strain
present
vaccin
respiratori
rout
vaccin
common
veterinari
medicin
aerosol
vaccin
rout
pulmonari
inhal
commerci
avail
cow
bovin
herp
viru
parainfluenza
viru
pig
salmonella
hors
influenza
streptococcu
equi
dog
bordetella
bronchiseptica
cat
felin
calciviru
felin
herpesviru
chicken
infecti
bronchiti
viru
infecti
laryngotrach
viru
newcastl
diseas
viru
almost
respiratori
veterinari
vaccin
live
attenu
pathogen
unit
state
billion
chicken
vaccin
yearli
use
live
attenu
vaccin
deliv
aerosol
spray
mani
biolog
agent
potenti
bioterror
biowarfar
caus
lifethreaten
respiratori
infect
would
probabl
dissemin
aerosol
thu
vaccineinduc
mucos
immun
may
advantag
compar
parenter
inject
respiratori
vaccin
increas
surviv
aerosol
exposur
deadli
agent
anim
studi
exampl
microspherebas
liquid
anthrax
vaccin
deliv
rout
mice
complet
protect
aerosol
challeng
anthrax
spore
two
dose
human
parainfluenzavirusvector
ebola
vaccin
highli
immunogen
macaqu
protect
anim
lethal
ebola
viru
challeng
powder
formul
anthrax
vaccin
cpg
odn
administ
intranas
rabbit
also
provid
full
protect
bioterror
agent
respiratori
vaccin
shown
increas
protect
aerosol
challeng
includ
francisella
tularensi
tularemia
staphylococc
enterotoxin
b
burkholderia
mallei
glander
pesti
plagu
threaten
pandem
sever
acut
respiratori
syndrom
sar
actual
one
influenza
illustr
critic
need
prompt
develop
new
vaccin
rapid
deliveri
countri
potenti
affect
respond
futur
threat
new
vaccin
may
requir
respiratori
deliveri
may
use
variou
reason
alreadi
describ
simpl
devic
singleus
drypowd
inhal
could
distribut
mail
selfadminist
mass
vaccin
congreg
crowd
convent
campaign
deem
unwis
deliveri
salmonellavector
vaccin
sar
coronaviru
result
higher
product
specif
igg
iga
orogastr
intraperiton
intraven
administr
provid
high
level
specif
cytotox
lymphocyt
balbc
mice
two
dose
live
attenu
influenza
vaccin
fulli
protect
mice
ferret
pulmonari
replic
homolog
heterolog
strain
wildtyp
crossprotect
divers
strain
would
desir
pandem
vaccin
potenti
rapid
chang
influenza
surfac
antigen
exampl
administr
inactiv
wholeviru
vaccin
adjuv
elicit
immun
respons
siga
nasal
lung
vagin
lavag
igg
serum
show
protect
immun
lethal
challeng
crossclad
protect
also
aerosol
laiv
provid
heterolog
protect
pandem
viru
challeng
ferret
cutan
jetinject
respiratori
method
vaccin
deliveri
overcom
danger
often
hidden
cost
tradit
needl
syring
longstand
mani
novel
techniqu
may
offer
advantag
term
dosag
spare
immun
respons
econom
thermost
patient
user
prefer
expand
venu
use
mani
promis
techniqu
describ
chapter
howev
face
daunt
obstacl
bridg
gap
success
proof
principl
anim
model
academ
laboratori
expens
complic
seri
clinic
trial
particularli
mani
target
diseas
lack
conveni
laboratori
assay
predict
protect
relat
studi
regulatori
step
achiev
licensur
inde
financ
stage
requir
investor
envis
method
commercialscal
manufactur
predict
demand
rather
monopsonist
market
final
downstream
outlet
vaccin
r
pipelin
public
health
immun
program
policymak
endus
purchas
nowaday
independ
philanthrop
entiti
must
convinc
econom
analys
consider
pay
fruit
immun
scienc
perhap
new
technolog
describ
illustr
herein
help
fulfil
wide
admir
goal
peopl
deserv
chanc
live
healthi
product
live
coauthor
j
p
coinventor
correspond
financi
interest
aerovax
aerovectrx
inc
crear
inc
drypowd
inhal
cdc
crear
devic
illustr
figur
f
respect
